Poster Session 4 – Thursday, December 8, 2022: 7:00 am CT
   
  Treatment - Advanced Disease Treatment: Advanced Therapy - Targeted
P4-01-01 RIBANNA  5th interim analysis: Matched-pair analysis of progression-free survival (PFS) across treatment cohorts and comparison of frontline ribociclib + endocrine therapy PFS data from RIBANNA vs MONALEESA trials, in HR+, HER2– ABC
Jackisch C, Brucker C, Decker T, Engel A, Fasching PA, Göhler T, Janssen J, Köhler A, Lüdtke-Heckenkamp K, Lüftner D, van Mackelenbergh M, Marmé F, Nusch A, Rautenberg B, Reimer T, Schmidt M, Weide R, Wimberger P, Roos C, Wöckel A. Department of Obstetrics and Gynecology, Sana Klinikum Offenbach, Germany; Department of Obstetrics and Gynecology, Klinikum Nürnberg, Paracelsus Medical University, Nürnberg, Germany; Oncology Ravensburg, Ravensburg, Germany; Winicker Norimed GmbH, Nürnberg; Department of Obstetrics and Gynecology, University Hospital Erlangen, Erlangen, Germany; Onkozentrum Dresden/ Freiberg, Dresden, Germany; Medizinische Studiengesellschaft Nord-West GmbH, Westerstede, Germany; Practice for Hematology and Oncology, Langen, Germany; Department of Oncology and Hematology, Niels-Stensen-Kliniken, Georgsmarienhütte, Germany; Department of Hematology, Oncology and Tumor Immunology, Charité University Hospital, Berlin, Germany; Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Med. Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany; Practice for Hematology and Medical Oncology Velbert, Velbert, Germany; Universitätsklinikum Freiburg, Freiburg, Germany; University Hospital Rostock, Rostock, Germany; Universität Mainz, Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Mainz, Germany; InVO - Institut für Versorgungsforschung in der Onkologie, Koblenz, Germany; Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Department of Obstetrics and Gynecology, University Hospital Würzburg, Würzburg, Germany.
P4-01-02 Results from a dose escalation phase 1b study of palbociclib and avelumab in advanced breast cancer in the PAveMenT Trial
Okines AF, Moghadam H, Sparks L, Mohammed K, Dunne K, Nerurkar A, Osin P, Swift C, Sardinha R, Turner N. The Royal Marsden NHS Foundation Trust; The Royal Marsden Hospital NHS Foundation Trust; The Royal Mardsen Hospital; The Institute of Cancer Research.
P4-01-03 Progression-free survival and patient-reported outcomes in HR+, HER2– ABC patients treated with first-line ribociclib + endocrine therapy (ET) or ET monotherapy or chemotherapy in real world setting: 5th interim analysis of RIBANNA
Fasching PA, Brucker C, Decker T, Engel A, Göhler T, Jackisch C, Janssen J, Köhler A, Lüdtke-Heckenkamp K, Lüftner D, van Mackelenbergh M, Marmé F, Nuasch A, Rautenberg B, Reimer T, Schmidt M, Weide R, Wimberger P, Roos C, Wöckel A. Department of Obstetrics and Gynecology, University Hospital Erlangen, Erlangen, Germany; Department of Obstetrics and Gynecology, Klinikum Nürnberg, Paracelsus Medical University, Nürnberg, Germany; Oncology Ravensburg, Ravensburg, Germany; Winicker Norimed GmbH, Nürnberg; Onkozentrum Dresden/ Freiberg, Dresden, Germany; Department of Obstetrics and Gynecology, Sana Klinikum Offenbach, Germany; Medizinische Studiengesellschaft Nord-West GmbH, Westerstede, Germany; Practice for Hematology and Oncology, Langen, Germany; Department of Oncology and Hematology, Niels-Stensen-Kliniken, Georgsmarienhütte, Germany; Department of Hematology, Oncology and Tumor Immunology, Charité University Hospital, Berlin, Germany; Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Med. Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany; Practice for Hematology and Medical Oncology Velbert, Velbert, Germany; Universitätsklinikum Freiburg, Freiburg, Germany; University Hospital Rostock, Rostock, Germany; Universität Mainz, Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Mainz, Germany; InVO - Institut für Versorgungsforschung in der Onkologie, Koblenz, Germany; Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Department of Obstetrics and Gynecology, University Hospital Würzburg, Würzburg, Germany.
P4-01-04 Phase IV multicenter study evaluating RWE and the safety of talazoparib in patients with locally advanced or metastatic negative HER2 breast cancer and a BRCA1/2 mutation (ViTAL) - Cohort 2: patients treated according to the EMA
Loirat D, Duboys de la barre M, Villanueva C, Mailliez A, Isambert N, Moreau L, Jacquet E, Spaëth D, Creisson A, Jouannaud C, Legouffe E, Delbado M, Deiana L, Soibinet P, Hrab I, Grellety T, Dohollou N, Longo R, Thery J-C, Fumet J-d, Zineb S, Pujol P, de la Motte Rouge T. Institut Curie, Medical Oncology Department and D3i, Paris, France; Institut Régional du Cancer Montpellier, Montpellier, France; Clinique Clementville, Montpellier, France; Oscar LAMBRET Centre; CHU de la Milétrie, Poitiers, France; Pôle Santé République, Clermont-Ferrrand, France; CHU Grenoble Alpes, La Tronche, France; Polyclinique de Gentilly, Nancy, France; Centre Antoine-Lacassagne, Nice, France; Institut Godinot; Institut de Cancérologie du Gard, Nîmes, Franc; Groupe hospitalier Diaconesses Croix Saint-Simon, Paris, France; CHU de Brest, Brest, France; Institut Godinot, Reims, France; Centre François Baclesse, Caen, France; Centre Hospitalier de la Côte Basque, Bayonne, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Chr Metz Thionville, Metz, France; Centre Henri Becquerel, Rouen, France; Centre Georges François Leclerc, Dijon, France; Chr Metz Thionville, Metz, France; CHU and University of Montpellier, Montpellier, France; Centre Eugene Marquis.
P4-01-05 Machine learning to predict treatment response and tolerability in HR+, HER2– advanced breast cancer: German study AI4ANNA
Fasching PA, Wöckel A, Tesch H, Volz B, Pritzsche U, Bachmann M, Vodencarevic A, Kreuzeder J, Lüftner D. Department of Obstetrics and Gynecology, University Hospital Erlangen, Erlangen, Germany; Department of Obstetrics and Gynecology, University Hospital Würzburg, Würzburg, Germany; Oncology Practice at Bethanien Hospital Frankfurt, Frankfurt, Germany; Ansbach University of Applied Sciences, Ansbach, Germany; HMS Analytical Software GmbH, Heidelberg, Germany; Novartis Pharma GmbH, Nürnberg, Germany; Department of Hematology, Oncology and Tumor Immunology, Charité University Hospital, Berlin, Germany.
P4-01-06 LP-184, an acylfulvene class small molecule therapeutic, is synthetically lethal in HR deficient and PARP inhibitor resistant triple negative breast cancer
Kulkarni A, Biyani N, Brullé-Soumaré L, Cairo S, Sharma P, Bhatia K. Lantern Pharma; Xentech.
P4-01-07 FS-1502, an anti-HER2 ADC, in patients with HER2‑expressing advanced solid tumors: A phase 1a dose-escalation study
Li Q, Wang X, Cheng Y, Liu Y, Chang J, Wang Z, Wu C, Wang M, Hui A-M, Wu Z, Jin Y, Huang X, Zhong L, Diao L, Zhao H, Xu B. Cancer Hospital Chinese Academy of Medical Sciences; Sri Run Run Shaw Hospital, Zhejiang University School of Medicine; Jilin Cancer Hospital; The Fourth Hospital of Hebei Medical University; Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences; Phase I ward, Department of Oncology; The Fourth Hospital of Hebei Medical University; Fosun Pharma USA Inc.; Beijing Fosun Pharmaceutical Research and Development Co., Ltd.; Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
P4-01-08 Efficacy of PARP inhibitors in patients With BRCA1/2-related breast cancer with prior platinum exposure: A systematic review and meta-analysis
Marinho AD, Mella S Pessoa B, Brandao GR, Da Silva CH, Reis PA, Comini ACM, Batalini F. Federal University of the State of Rio de Janeiro; Federal University of Amazonas; Federal University of Health Sciences of Porto Alegre (UFCSPA); Federal University of Rio Grande do Norte; A.C. Camargo Cancer Center; Mayo Clinic.
P4-01-09 Characterization of breast cancer brain metastases overall and progression-free survival and timing of cyclin-dependent kinase 4/6 inhibitor use: Retrospective single institution experience
Chew Minmin S, Chen Y, Kelly D, Robson ME, Seidman AD. Memorial Sloan Kettering Cancer Center.
P4-01-10 Evaluating the safety of tucatinib in combination with trastuzumab and capecitabine for human epidermal growth factor 2 (HER2)-positive metastatic breast cancer in a real-world setting
Moore H, Anders C, Sammons SL, Erkanli A, Parish A, DiCola C. Duke Cancer Institute; Duke University Medical Center / Duke Cancer Institute; Duke University; Duke University Hospital.
P4-01-11 Withdrawn
P4-01-12 BAT8006, a novel FRα ADC with strong bystander effect, for the treatment of advanced solid tumor
Mai S, Mei X, Tang W, Zhou X, Qi X, Zhong Z, Li S, Fan J, Gan J, Tan B, Qi Y, Guo Y, Li S, Yu J-C. Bio-Thera Solutions, Ltd., Guangzhou, China.
P4-01-13 A retrospective study of anlotinib in patients with HER-2 negative metastatic breast cancer after prior two or more lines treatment
Sun J, Tang Y, Liu X, Li J, Xia J, Xu L, Guo J, Wang J, Guo S, Sheng Z, Zhang Y, Yuan Y. Anyang cancer hospital.
P4-01-14 Changes in the genomic spectrum of actionable alterations in HER2 negative metastatic breast cancer in serial cell free DNA (cfDNA) analysis
Bar Y, Keenan JC, Ryan L, Juric D, Shin J, Wander SA, Spring LM, Moy B, Ellisen LW, Isakoff SJ, Bardia A, Vidula N. Massachusetts General Hospital Cancer Center, and Oncology Division, Tel Aviv Sourasky Medical Center; Cancer Center, Massachusetts General Hospital; Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital, Harvard Medical School, Boston, MA.
P4-01-15 Preliminary results from a phase 2 study of praluzatamab ravtansine (CX-2009) in patients with advanced breast cancer (ABC)
Miller K, Tolaney SM, Emens LA, Kim S-B, Hamilton EP, Saura C, Sanz L, Boni V, Lynce F, Cejalvo JM, Crozier J, Wang S, Uppal H, Hannah AL, Hurvitz SA. Indiana University Simons Comprehensive Cancer Center, Indianapolis, IN, USA; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA, USA; Asan Medical Center, Seoul, Republic of Korea; Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN, USA; Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Barcelona, Spain; Vall d´Hebron Institute of Oncology, Barcelona, Spain; NEXT Madrid, University Hospital Quironsalud, Madrid, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Baptist MD Anderson Cancer Center, Jacksonville, FL, USA; CytomX Therapeutics, Inc., South San Francisco, CA, USA; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
P4-01-16 High levels of RSK2 in breast cancer patients is associated with longer PFS in patients treated with PMD-026, a first in class RSK inhibitor
Wang JS, Beeram M, Chalasani P, Mina L, Shatsky RA, Hurvitz SA, Trivedi MS, Wesolowski R, Han HS, Patnaik A, Bahadur S, Huynh M-m, Jayanthan A, Los G, Dunn SE, Dorr A. Florida Cancer Specialists/Sarah Cannon Research Institute; The START Center; University of Arizona Cancer Center; Banner MD Anderson Cancer Center; UC San Diego Health; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Columbia University Irving Medical Center; James Cancer Hospital and the Ohio State University Comprehensive Cancer Center; H. Lee Moffitt Cancer Center, Tampa, FL, USA; START San Antonio; Phoenix Molecular Designs.
P4-01-17 Phase I/II study of pembrolizumab in combination with oral binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer
Shumsri S, Larson JJ, Tenner KS, He J, Polley M-Y, Weidner MT, Arnold AN, Haley D, Advani P, Sideras K, Moreno-Aspitia A, Perez EA, Knutson KL. Mayo Clinic, Jacksonville; Mayo Clinic; University of Chicago.
P4-01-18 Real-world second-line treatment patterns and associated clinical outcomes for 2795 patients with advanced HR+ HER2- breast cancer treated with first-line CDK4/6 inhibitors
Clifton KK, Wander SA, Ma CX, Davis AA, Weipert C, Zhang N, Bucheit L. Washington University in St Louis School of Medicine; Massachusetts General Hospital, Harvard Medical School, Boston, MA; Washington University School of Medicine; Guardant Health.
P4-01-19 Real world statistics on CDK4/6 inhibitor use in metastatic hormone receptor positive and HER2-negative breast cancer with a focus on age
Monahan K, Kamaraju S, Cheng YC, Retseck J, Sriram D, Burfeind J, Chitambar C Chaudhary LN. Medical College of Wisconsin Affiliated Hospitals; Medical College of Wisconsin.
P4-01-20 Phase IV study evaluating talazoparib in patients with locally advanced or metastatic negative HER2 breast cancer and a somatic or germline BRCA1/2 mutation (ViTAL) – Analysis of cohort 1 according to hormonal receptor status
Loirat D, Duboys de la barre M, Thery J-C, Hrab I, Jouannaud C, Mouysset J-L, Salabert L, Soibinet P, Mailliez A, Valery R, Creisson A, Villanueva C, Dohollou N, Fumet J-d, Grellety T, Perez-staub N, Lachaier E, Iltis-roux A, Delbado M, Najem A, Le Scodan R, Curtit E, Aldabbagh K, Pujol P, de la Motte Rouge T. Institut Curie, Medical Oncology Department and D3i, Paris, France; Institut Régional du Cancer Montpellier, Montpellier, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; Institut Godinot; Hôpital Privéde Provence, Aix en Provence, France; Institut Bergonié, Bordeaux, France; Institut Godinot, Reims, France; Oscar LAMBRET Centre; Centre médical MGEN, Sainte-Feyre, France; Centre Antoine-Lacassagne, Nice, France; Clinique Clementville, Montpellier, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Centre Georges François Leclerc, Dijon, France; Centre Hospitalier de la Côte Basque, Bayonne, France; Hôpital Franco-Britannique, Levallois-Perret, France; Centre Picardie, Amiens, France; Clinique Sainte-Anne, Strasbourg, France; Groupe hospitalier Diaconesses Croix Saint-Simon, Paris, France; Centre Hospitalier de Boulogne-sur-Mer, Boulogne-sur-Mer, France; Centre Hospitalier Privé Saint-Grégoire, Saint-Grégoire, France; CHRU Besançon, Besançon, France; Polyclinique Saint Côme, Compiègne, France; CHU and University of Montpellier, Montpellier, France; Centre Eugene Marquis.
P4-01-21 Phase 2 study of the CDK4/6 inhibitor FCN-437c in combination with Fulvestrant or Letrozole and Goserelin in patients with HR+, HER2– advanced breast cancer
Shi J, Li W, Tong Z, Zang A, Zeng X, Wang S, Huang T, Wang Y, Song Y, Kang L, Lv Z, Shi Y, Yang H, Wu J, Yin Y, Liang Y, Tan J, Ming J, Yang Y, Luo S, Gui X, Hui A-M, Wu Z, Tian L, Yang Y, Diao L, Zhang W, Zhang Y, Liu Y. The Fourth Hospital of Hebei Medical University; The First Hospital of Jilin University; Tianjin Medical University Cancer Institute and Hospital; Affiliated Hospital of Hebei University; Chongqing University Cancer Hospital; Jiangsu Province Hospital; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Sun Yat-sen Memorial Hospital, Sun Yat-sen University; The First Hospital of Jilin University; Department of Breast Medical Oncology, Tianjin Medical University Cancer Institute and Hospital; Affiliated Hospital of Hebei University; Chongqing University Cancer Hospital; Department of Medical Oncology, Jiangsu Province Hospital; Department of Breast Surgery, Jiangsu Province Hospital; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Fosun Pharma USA Inc.; Beijing Fosun Pharmaceutical Research and Development Co., Ltd.; Avanc Pharmaceutical Co. Ltd.; The Fourth Hospital of Hebei Medical University.
P4-01-22 Clinical outcomes of metastatic breast cancer patients treated with poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi): the Mayo Clinic experience
Jahan N, Taraba J, Giridhar KV, Leon-Ferre RA, Tevaarwerk AJ, Cathcart-Rake E, O'Sullivan CC, Peethambaram P, Hobday TJ, Ruddy KJ, Mina LA, Advani P, Batalibi F, Goetz MP, Haddad TC, Couch FJ, Yadav S. University of Alabama at Birmingham; Mayo Clinic; Mayo Clinic, Rochester, MN, USA.
P4-01-23 Updated data from the phase 1 trial of DZD1516, a BBB-penetrant selective HER2 inhibitor, in patients with HER2 positive metastatic breast cancer
McAndrew NP, Hu X, Zhang J, Wang X, Yu W, Pan X.
P4-01-24 Targeting receptor tyrosine kinases in overcoming tamoxifen resistance and dormancy in invasive lobular cancer
Ramaswamy B, Pramod N, Kulkarni A, Rima XY, Reátegui E, Shankar E, Majumder S. The Ohio State University Comprehensive Cancer Center; Cleveland Clinic; The Ohio State University.
P4-01-25 Safety analysis after 11 years of follow-up of the randomized phase III trial SAKK22/99: upfront chemotherapy in advanced HER2 positive breast cancer
Rabaglio M, Dietrich D, Scheibe B, Ruhstaller T, Nole F, Eppenberger S, Oehlschlegel C, Hess D, Mamot C, Munzone E, Pestalozzi B, Aebi S, Vetter M, Thuerlimann B, von Moos R, Zaman K, Pagani O. Department of Medical Oncology; Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland; Swiss Group for Clinical Cancer Research, Center of Competence, Bern, Switzerland; Tumor and Breast Center of Eastern Switzerland; European Institute of Oncology, Milano, Italy; Molecular Pathology, University Hospital, Basel, Switzerland; Pathology, Kantonsspital, St. Gallen, Switzerland; Department of Internal Medicine, Kantonsspital, St. Gallen, Switzerland; Oncology, Kantonsspital, Aarau, Switzerland; European Institute of Oncology, IRCCS, Milano, Italy; Department of Medical Oncology and Hematology, University Hospital, Zurich, Switzerland; Medical Oncology, Luzerner Kantonsspital, Switzerland; Basel University Hospital and Cantonal Hospital Baselland; Swiss Group for Clinical Cancer Research; Breast Center, St. Gallen, Switzerland; Breast Center, Lausanne University Hospital CHUV, Lausanne, Switzerland; Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz; Geneva University Hospitals, Lugano University and Swiss Group for Clinical Cancer Research (SAKK).
P4-01-26 Real-world treatment duration of subsequent therapy after palbociclib (PAL) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC) in Japan
Sawaki M, Muramatsu Y, Togo K, Iwata H. Aichi Cancer Center; Pfizer Japan Inc.; Aichi Cancer Center Hospital, Aichi, Japan.
P4-01-27 Prognosis and treatment landscape of HER2-positive metastatic breast cancer (MBC) before the availability of tucatinib and trastuzumab-deruxtecan: Results from the Austrian AGMT_MBC-Registry
Gampenrieder SP, Rinnerthaler G, Tinchon C, Petzer A, Balic M, Heibl S, Sandholzer M, Zabernigg AF, Egle D, Hager C, Pichler P, Roitner F, Andel J, Strasser-Weippl K, Knauer M, Hubalek M, Singer CF, Greil R. Department of internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute – Laboratory for Immunological an Molecular Cancer Research (SCI-LIMCR), Paracelsus Medical University, Salzburg Austria, Cancer Cluster Salzburg, Austria; Internal Medicine - Department for Haemato-Oncology, LKH Hochsteiermark, Leoben, Austria; Internal Medicine I for Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Barmherzige Schwestern – Elisabethinen, Linz, Austria; Division of Oncology, Department for Internal Medicine, Medical University Graz, Graz, Austria; Department of Internal Medicine IV, Klinikum Wels-Grieskirchen GmbH, Wels, Austria; Department of Internal Medicine II, Academic Teaching Hospital Feldkirch, Feldkirch, Austria; Department of Internal Medicine, County Hospital Kufstein, Kufstein, Austria; Department of Gynaecology, Medical University Innsbruck, Innsbruck, Austria; Department of Gynecology and Obstetrics, City Hospital, Dornbirn, Austria; University Hospital St.Pölten, Department for Internal Medicine 1, St. Pölten, Austria; Department of Internal Medicine II, Hospital Braunau, Braunau, Austria; Department of Internal Medicine II, Pyhrn-Eisenwurzen Klinikum Steyr, Steyr, Austria; Department of Medicine I, Clinic Ottakring, Vienna, Austria; Tumor and Breast Center Eastern Switzerland, St. Gallen, Switzerland; Department of Gynecology, Breast Health Center Schwaz, Schwaz, Austria; Department of Gynecology and Obstetrics and Comprehensive Cancer Center, Medical University of Vienna, Austria.
P4-01-28 Palbospain: Observational analysis of first-line therapy with Palbociclib in patients with HR+/HER2- metastatic breast cancer (MBC) in real-life conditions
Martínez-Jáñez N, Bellet Ezquerra M, Henao F, Manso L, Antón A, Zamora P, Morales Murillo S, Tolosa P, Andrés R, Calvo L, Galve E, Lopez R, Ayala de la Peña F, López-Tarruella S, Boronat L, Martos T, Chacón JI, Álvarez I, de la Haba-Rodríguez J, Moreno Antón F. Medical Oncology Hospital Universitario Ramón y Cajal. Madrid. Spain. GEICAM Spanish Breast Cancer Group; Vall d’Hebron Institute of Oncology (VHIO) and Vall d’Hebron University Hospital, and SOLTI Group; Medical Oncology Hospital Virgen de la Macarena. Sevilla. Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario Miguel Servet. GEICAM Spanish Breast Cancer Group; Hospital Universitario de La Paz, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; SOLTI Cancer Research Group, Barcelona, Spain/Medical Oncology Department, Hospital 12 de Octubre, Madrid; Hospital Clínico Universitario Lozano Blesa. GEICAM Spanish Breast Cancer Group; Oncology Department-Universitary Hospital A Coruña; Hospital Universitario de Basurto; Medical Oncology Hospital Clínico Universitario de Santiago CHUS. La Coruña Spain; Hematology and Oncology Department, Hospital Universitario Morales Meseguer, Murcia, Spain; Hospital Universitario Gregorio Marañón. CIBERONC-ISCIII. GEICAM Spanish Breast Cancer Group; Medical Oncology Hospital de la Santa Creu i Sant Pau. Barcelona. Spain; Medical Oncology. Hospital del Mar. Barcelona. Spain; Hospital Universitario de Toledo. GEICAM Spanish Breast Cancer Group; Hospital Universitario Donostia-BioDonostia. GEICAM Spanish Breast Cancer Group; Instituto Maimonides de Investigacion Biomedica, Hospital Reina Sofia, Universidad de Córdoba. GEICAM Spanish Breast Cancer Group; Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), CIBERONC, Madrid, Spain.
P4-01-29 Ribociclib plus letrozole alters the immune subset composition in older (≥70 yrs.) patients with HR+/HER2- metastatic breast cancer
Lambrechts Y, Hatse S, Kenis C, Decoster L, de Azambuja E, Jerusalem G, Neven P, Dal Lago L, Denys H, Vuylsteke P, Cornelis F, Punie K, Floris G, Desmedt C, Laenen A, Pondé N, Wildiers H. KU Leuven; Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven, Belgium; UZ Leuven; Department of Medical Oncology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Brussels, Belgium; Academic Trials Promoting Team and Medical Oncology Department, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B.), Brussels, Belgium; Department of Medical Oncology, University Hospital of Liege, CHU Sart Tilman, Liege, Belgium; Universitair Ziekenhuis Leuven, Leuven, Belgium; Institut Jules Bordet, Brussels, Belgium; Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium; CHU UCL Namur – Site Sainte-Elisabeth; Medical Oncology Department, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute and University Hospitals Leuven, Belgium; University Hospitals Leuven; Laboratory for Translation Breast Cancer Research/KU Leuven; Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, Brazil.
P4-01-30 Real-world treatment patterns and survival among adults with metastatic breast cancer with BRCA1/2 mutations
Bobbili P, Ivanova J, Solit DB, Mettu N, McCall S, Dhawan M, DerSarkissian M, Arondekar B, Chang J, Niyazov A, Lee J, Huq RJ, Green M, Turski M, Muthukumar A, Guo M, Duh MS, Oh W. Analysis Group, Inc.; Pfizer Inc.; Memorial Sloan Kettering Cancer Center; Duke University Medical Center; Duke University School of Medicine; UCSF Hellen Diller Cancer Center; Analysis Group, Inc.; American Association for Cancer Research; Duke University; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai.
P4-01-31 High incidence of Palbociclib related neutropenia in Asian patients associated with genetic polymorphisms
Huang K-J, Kuo T-H, Chao T-C, Liu C-Y, Tsai Y-F, Huang C-C, Tseng L-M, Hsu C-CR, Lai J-I. Department of Medicine, Taipei Veterans General Hospital; Department of Chemistry, National Taiwan University; Department of Oncology, Taipei Veterans General Hospital; Department of Transfusion Medicine, Taipei Veterans General Hospital; Department of Surgery, Taipei Veterans General Hospital.
P4-01-32 BAT8008, a novel Trop-2 ADC with strong bystander effect, for the treatment of Trop-2 positive cancer
Mei X, Tang W, Zhou X, Qi X, Mai S, Zhong Z, Li S, Fan J, Gan J, Tan B, Qi Y, Guo Y, Yu J-C, Li S. Bio-Thera Solutions, Ltd., Guangzhou, China.
P4-01-33 Withdrawn
P4-01-34 Benefits provided by antibody drug conjugates in overall survival outweighs those in progression-free survival for metastatic breast cancer: A class effect
Chen I-C, Lin C-H, Lu Y-S. Department of Medical Oncology, National Taiwan University Cancer Center; Graduate Institute of Oncology, National Taiwan University; Department of Medical Oncology, National Taiwan University Cancer Center; National Taiwan University Hospital, Taipei, Taiwan.
P4-01-35 A phase 1 study of the oral CDK7 inhibitor XL102 as a single agent and in combination therapy in patients With advanced solid tumors (QUARTZ-101): Initial results from the dose-escalation stage
Patnaik A, Barve M, Bhave M, Subbiah V, Rasco D, Bhatt A, Li J, Andrianova S, Shapiro G. START San Antonio; Mary Crowley Cancer Research, Dallas, TX, USA; Emory University School of Medicine, Atlanta, GA, USA; The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Exelixis, Inc., Alameda, CA, USA; Dana-Farber Cancer Institute, Boston, MA, USA.
P4-01-36 Real world data for Trastuzumab Deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases
Toler A, Bobolts LR, Mangurian M, Pozotrigo M, Wise C, Solomon H, Hartung N, Makielski R, Marur S, Ravindranathan M, Marur S. OncoHealth.
P4-01-37 Discontinuation of HER2+ targeted therapy among cancer survivors with metastatic HER2+ breast cancer: A case report
Hui LF, Shah NN, Hui RL. Kaiser Permanente Northern California; Kaiser Permanente.
P4-01-38 A single arm phase II trial of Palbociclib in combination with Tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer
Danciu OC, Hoskins K, Weiss J, Truica CI, Blaes A, Tamkus D, Rana J, Pavankumar T, Green L, Gao Y, Yu M, Zhao Q, Toppmeyer D, O'Regan R, Wisinski KB. University of Illinois Cancer Center; University of Illinois Chicago; Penn State Cancer Institute; University of Minnesota; Michigan State University; University of Nebraska Medical Center; University of Wisconsin Carbone Cancer Center; Rutgers Cancer Institute of New Jersey; University of Rochester Medical Center.
P4-01-39 Real-world efficacy of dual antiHER2 therapy in first line metastatic HER2-positive breast cancer and the possibility of prediction of long-term response
Križić M, Silovski T, Popović, M, Dedić Plavetić N. University Hospital Centre Zagreb.
P4-01-40 Real world data with off-label insurance approval of Trastuzumab Deruxtecan in metastatic breast cancer
Bobolts LR, Mangurian M, Marur S, Wise C, Pozotrigo M, Solomon H, Hartung N, Ravindranathan M, Makielski R, Marur S, Toler A. OncoHealth.
P4-01-41 Clinical outcome and toxicity profile of Cyclin-dependent kinase 4/6 inhibitors in combination with hormonal treatment in management of metastatic breast cancer patients: A Middle-East Real World Experience
Mostafa Gad A, AlSayed A, AlShibani A, Twegieri T, Suleman K, Ajarim D. King Faisal Specialist Hospital and Research Center.
P4-01-42 Pooled analysis of post-progression treatments after first-line ribociclib + endocrine therapy in patients with HR+/HER2− advanced breast cancer in the MONALEESA-2, -3, and -7 studies
Hamilton E, Spring LM, Fasching PA, Franco S, DeBoer RH, Cortés J, Kalinsky K, Juric D, Bardia A, Haftchenary S, Lteif A, Zarate JP, Cen L, Neven P. Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN, USA; Massachusetts General Hospital Cancer Center, Boston, MA, USA; Department of Obstetrics and Gynecology, University Hospital Erlangen, Erlangen, Germany; Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center CTIC, Bogotá D.C., Colombia; Peter MacCallum Cancer Centre, Victoria, Australia; International Breast Cancer Center (IBCC), Barcelona, Spain, ), Pangaea Oncology, Quironsalud Group, Madrid and Barcelona, Spain & Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, Spain; Winship Cancer Institute at Emory University, Atlanta, GA, USA; Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, MA, USA; Novartis Pharmaceuticals Canada, Montreal, QC, Canada; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Multidisciplinary Breast Center, University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium.
P4-01-43 PyrotInib in combination with Capecitabine for trasTUzumab-REsistant, HER2-positive advanced breast cancer (PICTURE): a multicenter phase 2 trial
Hu X, Cao J, Teng Y, Li H-P, Zhang L, Ouyang Q, Xie W, Pan Y, Song Z, Ling X, Wu X, Xu J, Li L, Ren L, Wang H, Zhou D, Luo J. Shanghai Cancer Center, Fudan University, Shanghai, China; Department of Medical Oncology, Fudan University Shanghai Cancer Center; Department of Breast Surgery, The First Hospital Of China Medical University; Department of Medical Oncology, Peking University Cancer Hospital & Institute; Department of Medical Oncology, Jiangsu Cancer Hospital; Department of Medical Oncology, Hunan Cancer Hospital; Department of Medical Oncology, Guangxi Medical University Cancer Hospital; Department of Medical Oncology, The First Affiliated Hospital Of USTC; Department of Breast Center, The Fourth Hospital Of Hebei Medical University; Department of Medical Oncology, The First Hospital Of Lanzhou University; Department of Medical Oncology, Affiliated Hospital Of Jiangnan University; Department of Breast Surgery, The Second Hospital Of Jilin University; Department of Medical Oncology, Qilu Hospital Of Shandong University; Department of Breast Surgery, Guangdong Provincial Hospital Of Chinese Medicine; Department of Medical Oncology, The Third Hospital Of Nanchang; Department of Breast Surgery, Shenzhen People'S Hospital; Department of Breast Surgery, Sichuan Provincial People'S Hospital.
   
  Prognostic and Predictive Factors: Biomarkers Predicting Tx Response: Predictive Biomarkers-Other
P4-02-01 Efficacy of HER2 ADCs against HER2 inhibitor resistance alterations in the PI3K and MAPK pathways in HER2-positive breast cancer
Ferraro E, Safonov A, Chen Y, White C, Marra A, Ahmed M, Acevedo B, Dang CT, Modi S, Solit DB, Norton l, Robson ME, Reis-Filho J, Chandarlapaty S, Razavi P. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
P4-02-02 Changes in treatment recommendation for patients with ductal carcinoma in situ using a 7-gene predictive biosignature: Analysis of the PREDICT study
Whitworth P, Shivers SC, Shah C, Patel R, Mittal K, Bremer T, Cox C. University of Tennessee; PreludeDx; Cleveland Clinic; Good Samaritan Hospital; University of South Florida Morsani College of Medicine.
P4-02-03 Transcriptomic signature score of Epithelial-Mesenchymal Transition (EMT) of a bulk tumor may not reflect that of cancer cells
Tokumaru Y, Wu R, Ukai J, Oshi M, Niwa Y, Mori R, Takabe K, Futamura M. Gifu University School of Medicine; Roswell Park Comprehensive Cancer Center; Yokohama City University Hospital; Breast Surgery, Gifu University Hospital.
P4-02-04 Serial monitoring of circulating tumor cells and circulating tumor DNA in metastatic lobular breast cancer identifies intra-tumor heterogeneity and precision and immuno-oncology biomarkers of therapeutic importance
Cani A, Dolce E, Turnbull A, Hu K, Liu C-J, Darga E, Robinson D, Wu Y-M, Thomas DG, Paoletti C, Tomlins S, Rae J, Udager A, Chinnaiyan A, Cobain EF, Hayes DF. University of Michigan; University of Michigan Medical School; University of Michigan Rogel Cancer Center; University of Michigan Comprehensive Cancer Center.
P4-02-05 Predictors of long-term durable response in de novo HER2 positive metastatic breast cancer and the real world treatment experience at two institutions
Smith CE, Marcom PK, Zahi M, Ko N. Boston Medical Center; Veracyte; Knight Cancer Institute, Oregon Health & Science University.
P4-02-06 Clinical and biological predictors of lymph node involvement in patients with early breast cancer for adjuvant treatment personalization
Pivetta T, Pastò B, Urbani M, Benozzi E, De Pascalis N, Perin T, Mileto M, Pasquotti B, Piccoli E, Vinante L, Bampo C, Bolzonello S, Garutti M, Nicoloso M, Corsetti S, Scalone S, da Ros L, di Nardo P, Lisanti C, Spazzapan S, Belletti B, Bartoletti M, Gerratana L, Massarut S, Puglisi F. IRCCS CRO; Centro di Riferimento Oncologico di Aviano (CRO), IRCCS; Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano; Department of Medicine (DAME), University of Udine, Udine, Italy and Department of Medical Oncology - CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy.
P4-02-07 A large real-world study of circulating tumor DNA in early breast cancer patients
Liu Q, Wu M, Li S, Li Y, Jin L, Shi Q, Zhang Y, Gong C. Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
P4-02-08 Towards precision radiation oncology: Endocrine therapy resistance as a biomarker for radiation resistance in ER-positive breast cancer
Udden SMN; Rahimi A, Kim DWN, Alluri P. UTSW; University of Texas Southwestern Medical Center; UTSW Medical Center.
P4-02-09 Evaluation of the automated liquid biopsy-breast cancer methylation (LBx-BCM) cartridge assay for predicting early disease progression and survival: TBCRC-005 Prospective Trial
Visvanathan K, Cope L, Fackler MJ, Considine M, Carey LA, Forero-Torres A, Ingle JN, Lin NU, Nanda R, Storniolo AM, Tulac S, Wu NC, Marla S, Venkatesan NR, Wolff AC, Sukumar S. Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, MD and Johns Hopkins Bloomberg School of Public Health, MD; Johns Hopkins Kimmel Cancer Center; Johns Hopkins; Johns Hopkins University; Alliance for Clinical Trials in Oncology; Seagen; Mayo Clinic; Medical Oncology, Dana-Farber Cancer Institute; Susan F. Smith Center for Women's Cancers, Dana-Farber Brigham Cancer Center; Harvard Medical School; University of Chicago, Chicago, IL, USA; Indiana University School of Medicine; Cepheid; Johns Hopkins University, Baltimore, USA; Johns Hopkins Kimmel Cancer Center and Bloomberg School of Public Health.
P4-02-10 MRI models by response predictive subtype for predicting pathologic complete response
Li W, Onishi N, Wolf DM, Newitt DC, Yau C, Wilmes LJ, Gibbs JE, Price ER, Joe BN, Kornak J, LeStage B, the I-SPY 2 Imaging Working Group and the I-SPY 2 Consortium, Esserman LJ, Van 't Veer L, Hylton NM. University of California, San Francisco; University of California, San Francisco and Buck Institute for Research on Aging, Novato, California; Quantum Leap Healthcare Collaborative.
P4-02-11 Moved to HER2 Session
P4-02-12 Validation of profile for the omission of local adjuvant radiotherapy (POLAR) in early-stage invasive breast cancer patients of the Scottish Conservation Trial
Taylor KJ, Bartlett JMS, Bennett J, Chang SL, Arrick B, Baehner F, Loane JF, Piper T, Mallon E, Dunlop J, Jack WJ, Caldwell J, Kunkler I, Williams LJ, Speers CW, Feng FY, Pierce LJ, Cameron DA. University of Edinburgh Cancer Research Centre, Institute of Genetics and Cancer; University of Edinburgh, Scotland, United Kingdom; Exact Sciences; Queen Elizabeth University Hospital, Glasgow; University of Edinburgh, Edinburgh, United Kingdom; University of Glasgow - Institute of Cancer Sciences; Scottish Clinical Trials Research Unit (SCTRU); NHS Lothian; Public Health Scotland; University of Edinburgh; Edinburgh Clinical Trials Unit, University of Edinburgh; University of Michigan; Department of Radiation Oncology, University of California San Francisco, San Francisco, CA; The University of Edinburgh, Edinburgh Cancer Research.
P4-02-13 Homologous recombination deficiency, RB-loss gene signatures, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2- early breast cancer: a correlative analysis of two phase II trials
Griguolo G, Miglietta F, Paré L, Generali DG, Frassoldati A, Musolino A, Spazzapan S, Vernaci G, Giarratano T, Lo Mele M, Bisagni G, Piacentini F, Tagliafico E, Cagossi K, Schiavi F, Pinato C, Prat A, Guarneri V, Dieci MV. Department of Surgery, Oncology and Gastroenterology, University of Padua; Division of Oncology 2, Veneto Institute of Oncology IOV-IRCCS; Reveal Genomics, Barcelona, Spain; UO Patologia Mammaria , ASST of Cremona; Azienda Ospedaliero Universitaria di Ferrara-Arcispedale Sant'Anna; University of Parma; Centro di Riferimento Oncologico di Aviano (CRO), IRCCS; Medical Oncology 2, Istituto Oncologico Veneto IOV IRCCS; Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS; Azienda Ospedaliera Universitaria di Padova; IRCCS AUSL Reggio Emilia; University of Modena and Reggio Emilia; Ospedale Bernardino Ramazzini, Carpi; Veneto Institute of Oncology IRCCS; Veneto Institute of Oncology IOV-IRCCS; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain; Breast Cancer Unit, IOB-Quirón Salud, Barcelona, Spain; Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS; Department of Surgery, Oncology and Gastroenterology, University of Padua; University of Padova.
P4-02-14 Gain of HER2 amplification in patients with HR+/HER2- and triple negative early breast cancer treated with neoadjuvant chemotherapy
Ferraro E, Chew Minmin S, Safonov A, Barrio AV, Modi S, Seidman AD, Wen HY, Brogi E, Robson ME, Dang CT. Memorial Sloan Kettering Cancer Center.
P4-02-15 Withdrawn
P4-02-16 Prognostic and predictive capacity of tumor infiltrating lymphocytes in the MA.20 regional radiotherapy trial
Riaz N, Chen B, Bane A, Gao D, Stovgaard E, Kos Z, Leung S, Shenasa E, Parulekar W, Chambers S, Nielsen T, Whelan TJ. University of British Columbia; Canadian Cancer Trials Group; University of Toronto; University of Copenhagen; University of British Columbia, Vancouver, BC, Canada; McMaster University.
P4-02-17 Impact of low hormone receptor expression on neoadjuvant chemotherapy response and patterns of care in early-stage HER2-negative breast cancer: a US National Cancer Database analysis
Quiroga D, Grimm M, Stephens J, Johnson K, Williams N, Sudheendra PK, Cherian MA, Stover DG, Pariser AC, Gatti-Mays M, Wesolowski R, Bazan JG, Beyer S, Park KU, Oppong B, Ramaswamy B, White J, Jhawar SR, Sardesai S. The Ohio State University Comprehensive Cancer Center; James Cancer Hospital and the Ohio State University Comprehensive Cancer Center; Ohio State University.
P4-02-18 Impact of clonal hematopoiesis on disease progression following CDK4/6 inhibitor therapy
Tao J, Sanchez Vela P, Safonov A, Ferraro E, Franch Exposito S, Menghrajani K, Ptashkin R, Comen E, Braunstein LZ, Robson ME, Chandarlapaty S, Reis-Filho J, Berger M, Zehir A, Levine R, Razavi P. New York Presbyterian-Weill Cornell, New York, NY, USA; Memorial Sloan Kettering Cancer Center, New York, NY, USA; Memorial Sloan Kettering Cancer Center;
P4-02-19 Development of a novel imaging biomarker to ascertain responsiveness to immunotherapy
Norris G, Pfeiffer J, Peterson J, Liadis N, Biancalana M, Lopez-Ramos D, Antony AK, Cook D. SimBioSys, Inc.
P4-02-20 Utility of the 70-gene signature and 10 year follow up in patients with early-stage breast cancer in a single institution study
Nasrazadani A, Gomez Marti JL, Rosenzweig MQ, McGuire M, Quinn K, Haan J, Houzelle A, Bhargava R, Audeh W, Brufsky AM. Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Pathology and Laboratory Medicine, Northwell Health Lenox Hill Hospital, New York City, New York, USA; University of Pittsburgh School of Nursing, Pittsburgh, PA, USA; Agendia NV; UPMC Magee-Womens Hospital; UPMC Hillman Cancer Center, University of Pittsburgh Medical Center.
P4-02-21 Withdrawn
P4-02-22 Breast microcalcification chemistry predicts DCIS prognosis
Nallala J, Calabrese D, Gosling S, Lips E, Factor R, Hall A, Pinder SE, Bouybayoune I, King L, Marks J, Lynch T, Pinto D, Wesseling J, Hwang ES, Rogers K, Stone N. University of Exeter; Cranfield University; Netherlands Cancer Institute; Duke University; School of Cancer and Pharmaceutical Sciences, King’s College London Faculty of Life Sciences and Medicine, London; Kings College London; www.DCIS411.com; Department of Surgery, Duke University Medical Center, Durham, NC, USA.
P4-02-23 Integrating tumor-intrinsic and immunological factors to improve locoregional treatment individualization of high-risk breast tumors
Stenmark Tullberg A, Sjöström M, Niméus E, Killander F, Lundstedt D, Kovács A, Holmberg E, Karlsson P. University of Gothenburg; University of California, San Francisco and Lund University; Lund University; Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
P4-02-24 A 3D visualization and prediction device for breast cancer surgeons and their patients
Parker A, Peterson J, Cole Jr JA, Whitman J, Hobbs N, Cook D, Antony AK. SimBioSys, Inc.
P4-02-25 Analysis of prognosis in different subtypes of invasive lobular carcinoma using a National Cancer Database Breast Cancer Registry of Japan
Adachi Y, Asaga S, Kumamaru H, Yamamoto Y, Imoto S, Jinno H. UT southwestern medical center; Department of Breast Surgery, Kyorin University School of Medicine; The University of Tokyo; Kumamoto University; Kyorin University Hospital; Department of Surgery, Teikyo University School of Medicine.
P4-02-26 Quantitative estrogen receptor expression affects pathologic complete response to neoadjuvant chemotherapy in patients with early-stage breast cancer with low expression of HER2
Iwase T, Fujii T, Yam C, Dong W, Shen Y, Tripathy D, Ueno NT. MD Anderson Cancer Institute; Cold Spring Harbor Laboratory/Northwell Health Cancer Institute; Breast Medical Oncology Department, The University of Texas MD Anderson Cancer Center; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
P4-02-27 Preliminary attainability assessment of real-world data for answering clinical questions about breast cancer brain metastases
Kim M-j, Kim HJ, Kang D, Ahn HK, Shin S-Y, Park S, Cho J, Park YH. Research Institute for Future Medicine, Samsung Medical Center; Department of Digital Health, Samsung Advanced Institute for Health Science and Technology, Sungkyunkwan University; Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University; Gachon University Gil Medical Center; Department of Digital Health, SAIHST, Sungkyunkwan University; Sungkyunkwan University; Samsung Medical Center, Sungkyunkwan University School of Medicine / Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University.
P4-02-28 EMP1 low expressing tumor is associated with cell proliferation and poor overall survival of ER-positive breast cancer patients
Ukai J, Tokumaru Y, Oshi M, Niwa Y, Mori R, Takabe K, Futamura M. Gifu University School of Medicine; Yokohama City University Hospital; Roswell Park Comprehensive Cancer Center; Breast Surgery, Gifu University Hospital.
P4-02-29 A 3D visualization method for breast cancer surgeons and patients
Parker A, Earnest TM, Pekis A, Kannan V, Peterson j, Cole Jr JA, Antony AK, Cook D. SimBioSys, Inc.
P4-02-30 Association between tumor infiltrating lymphocytes (TILs) and the HER2DX assay in early-stage of HER2-positive (HER2+) breast cancer
Sanfeliu E, Brasó-Maristany F, Dieci MV, Marín-Aguilera M, González-Farré B, Griguolo G, Pascual T, Galván P, Angelats L, Castillo O, Blasco P, Sirenko V, Jares P, Puig-Butillé JA, Paré L, Martínez A, Llombart-Cussac A, Cortés J, Vivancos A, Villagrasa P, Parker JS, Perou CM, Prat A, Conte P, Guarneri V. SOLTI Breast Cancer Research Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Faculty of Medicine and Pathology Department, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS); University of Padova; Reveal Genomics; Pathology Department, Hospital Clínic of Barcelona, Barcelona, Spain ; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain; Department of Surgery, Oncology and Gastroenterology, University of Padua; Division of Oncology 2, Veneto Institute of Oncology IOV-IRCCS; Hospital Clinic Barcelona; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain; Hospital Clinic, August Pi i Sunyer Biomedical Research Institute (IDIBAPS); Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS; Translational Genomics and Targered Therapeutics in Solid Tumors Lab ; August Pi i Sunyer Biomedical Research Institute (IDIBAPS; August Pi i Sunyer Biomedical Research Institute (IDIBAPS); Pathology Department & Molecular Biology CORE, Hospital Clinic Barcelona; Hospital Clinic Barcelona; Reveal Genomics; Hospital Arnau de Vilanova; FISABIO, Valencia, Spain. Catholic University, Valencia, Spain. Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain and Ridgewood, New Jersey, US; International Breast Cancer Center (IBCC), Barcelona, Spain; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain; Breast Cancer Unit, IOB-Quirón Salud, Barcelona, Spain; University of Padua; Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS; Department of Surgery, Oncology and Gastroenterology, University of Padua.
   
  Epidemiology, Risk, and Prevention: Epidemiology - Population Studies
P4-03-01 Persistence with adjuvant endocrine therapy in patients with early breast cancer at high risk of recurrence: a US-based real-world study
Sheffield KM, Vitko AS, Brown J. Eli Lilly & Company.
P4-03-02 Low-dose aspirin prescriptions and breast cancer recurrence: a Danish nationwide cohort study with up to 23 years of follow-up
Solmunde E, Pedersen RN, Nørgaard M, Mellemkjær L, Friis S, Ejlertsen B, Ahern TP, Cronin-Fenton D. Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark; Regional Hospital Central Jutland; Aarhus Universitetshospital; Danish Cancer Society Research Center; Rigshospitalet; Department of Surgery, The Robert Larner, M.D. College of Medicine, University of Vermont; Department of Clinical Epidemiology, Aarhus University Hospital.
P4-03-03 Elevated risk of breast cancer diagnosis in women with dense breasts reflects a similarly elevated risk of breast cancer onset that is robust to the effect of density on mammography sensitivity
Lange JM, Gard C, O'meara E, Etzioni R. Knight Cancer Research Institute, OHSU; New Mexico State University; Kaiser Research Institute Northwest; Fred Hutchinson Cancer Research Center.
P4-03-04 The first population level description of all women diagnosed with breast cancer in Costa Rica from 2008 to 2012 using data from the National Tumor Registry
Guzman PG, Ramirez-Pena E. National Cancer Institute.
P4-03-05 HER2 + breast cancer in Afro-Caribbean women in New York City
Cimpeanu E, Frangopoulos E, Ventura AM, Chiu E, Lin B, Taiwo E. State University of New York, Downstate Medical Center; Kings County Hospital Center, Clinical Medicine; University of Texas Southwestern Medical Center; Weill Cornell Medical College, Assistant Professor of Clinical Medicine.
P4-03-06 Clinical and socioeconomic disparities in treatment and survival between Hispanic and non-Hispanic Black women with non-metastatic triple-negative breast cancer
Alvarez Soto A, Bernal AM, Anampa Mesias J. University of Connecticut Hospital; PPD, part of Thermo Fisher Scientific; Albert Einstein College of Medicine, Bronx, NY.
P4-03-08 Breast cancer incidence rates in Japan turned into bimodal age distribution in this decade
Uchida K, Ohashi H, Nogi H, Kinoshita S, Nosaka R, Kamio M. Meiji-Yasuda Shinjuku Medical Center; The Jikei University School of Medicine.
P4-03-09 Risk of breast cancer after false-positive mammography recalls: a matched cohort study
Mao X, He W, Humphreys K, Yang H, Czene K. Karolinska Institutet; Zhejiang University; Fujian Medical University.
P4-03-10 Breast density and risk of breast cancer
Lynge E, Vejborg I, Lillholm M, Nielsen M, Napolitano G, von Euler-Chelpin M. Nykøbing Falster Hospital, University of Copenhagen; Gentofte Hospital; University of Copenhagen.
P4-03-11 Population-based survival outcomes of pure vs mixed invasive lobular breast carcinoma in Ontario, Canada
Lim D, Giannakeas V, Narod S, Metcalfe K. Women's College Hospital; Women's College Research Institute; University of Toronto.
P4-03-12 Withdrawn
P4-03-13 An evaluation of breast cancer recurrence data reported to the NCI SEER Program
Ramirez-Pena E, Negoita S. National Cancer Institute; National Cancer Institute/ Division of Cancer Control and Population Sciences.
P4-03-14 Proinflammatory dietary patterns and risk of total and subtypes of breast cancer among US women
Romanos-Nanclares A, Willett WC, Rosner BA, Stover DG, Asad S, Sardesai S, Holmes MD, Chen WY, Tamimi RM, Tabung FK, Eliassen AH. Brigham and Women's Hospital and Harvard Medical School; Harvard T.H. Chan School of Public Health; Ohio State University; The Ohio State University Comprehensive Cancer Center; Brigham and Women’s Hospital and Harvard Medical School & Harvard T.H. Chan School of Public Health; Dana-Farber Cancer Institute and Harvard Medical School; Weill Cornell Medicine, New York, NY, USA.
P4-03-15 Does age affect outcome? Data from a large cohort from British Columbia, 2005-2014
Jackson EB, Gondara L, Speers CH, Gelmon K. BC Cancer Vancouver; BC Cancer Agency, Vancouver, British Columbia, Canada.
P4-03-16 Association between tamoxifen and the incidence of cataract in ductal carcinoma in situ patients
Kim D, Park W-C, Jeon S, Lee HS, Yoon CI. Seoul St Mary’s Hospital; 2Biostatistics Collaboration Unit, Yonsei University College of Medicine.
P4-03-17 Parity, use of statins and low-dose aspirin, and breast cancer risk – data from two large cohort studies
Schmidt JA, Fournier A, Cairat M, Mailhac A, Sørensen H, Gunter M, Cronin-Fenton D. Aarhus University; Inserm; International Agency for Research on Cancer and Inserm; Aarhus University and Aarhus University Hospital; Department of Clinical Epidemiology, Aarhus University Hospital.
P4-03-18 Group-based trajectories of endocrine therapy adherence and risk of recurrence in a Danish premenopausal breast cancer cohort
Woolpert KM, Schmidt JA, Ahern TP, Lash TL, Collin LJ, Ejlertsen B, Cronin-Fenton D. Department of Clinical Epidemiology, Aarhus University Hospital; Aarhus University; Department of Surgery, The Robert Larner, M.D. College of Medicine, University of Vermont; Rollins School of Public Health, Emory University; Huntsman Cancer Institute, University of Utah; Rigshospitalet.
P4-03-19 Expected real-world impact of escalation and de-escalation of Her2-directed therapy in breast cancer patients receiving neoadjvuant therapy
Mollenthiel A, Morris A, Lauren C, Simmons C. BC Cancer; BCCA - Vancouver Cancer Centre.
P4-03-20 Association between reproductive factors (parity and age first full term birth) and the frequency of estrogen receptor negative breast cancer according to age at diagnosis
Vangoitsenhoven M, Theys E, Van Baelen K, Laenen A, Desmedt C, Floris G, Wildiers H, Punie K, Han S, Baert T, Amant F, Smeets A, Nevelsteen I, Vanhoudt R, Neven P. University Hospitals Leuven / RZ Tienen; KU Leuven; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium; Laboratory for Translation Breast Cancer Research/KU Leuven; University Hospitals Leuven; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute and University Hospitals Leuven, Belgium; Department of Surgical Oncology, University Hospitals Leuven, Leuven, Belgium; Universitair Ziekenhuis Leuven, Leuven, Belgium.
P4-03-21 Racial disparities in survival trends in patients with metastatic Hormone receptor positive/Her 2 negative breast cancer: a SEER population-based study
Alvarez Soto A, Bernal AM, Anampa Mesias J. University of Connecticut Hospital; PPD, part of thermo Fisher scientific; Albert Einstein College of Medicine, Bronx, NY.
P4-03-22 Linking internal medicine care to metastatic breast cancer patients for success: LIMBS
Kaler AJ, Singareeka Raghavendra A, Kirklin GT, Cunningham D, Manzullo E, Tripathy D, Razouki Z. The University of Texas MD Anderson Cancer Center; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
P4-03-23 Comparison of breast cancer vs cardiovascular disease risk and uptake of chemoprevention vs statins in a cohort of predominantly Hispanic women undergoing screening mammography
Nilan L, McDermid MM, Amenta JN, McGuinness JE, Crew KD, Kukafka R. Columbia University Vagelos College of Physicians & Surgeons; Columbia University; Columbia University Irving Medical Center.
P4-03-24 State variation in racial and ethnic disparities in triple-negative breast cancer rates: NPCR-SEER incidence data, 2015-2019
Sung H, Wiese D, Jatoi I, Jemal A. American Cancer Society; University of Texas Health Science Center, San Antonio.
P4-03-25 Patient-level predictors of skipping screening mammograms during the COVID-19 pandemic at a large tertiary care center in Texas
Nemati Shafaee M, Rosales O, Kirby RP, Ortiz-Perez T, Gilman L, Hardeman A, Bhavsar Bhakta P, Amos C, Oluyomi A. Baylor College of Medicine.
P4-03-26 Blood DNA methylation and breast cancer: A prospective case-control analysis in the breast cancer prospective family study cohort
Wu H, Castano A, Liao Y, Santella R, Brenner D, Terry MB, Tycko B. Columbia University; Hackensack Meridian Health Center for Discovery and Innovation.
P4-03-27 The impact of sociodemographic disparities on overall survival of adolescent and young adults (AYA) with invasive breast cancer
Lopetegui-Lia N, Thayyil Jayakrishnan T, Barot S, Wei W, Kruse M. Cleveland Clinic Foundation; Cleveland Clinic.
P4-03-28 Patient reported symptom burden amongst immigrant and Canadian long-term resident women undergoing breast cancer surgery
Parvez E, Chu MM, Kirkwood D, Doumouras A, Bogach J. McMaster University; IC/ES.
P4-03-29 Impact of the COVID-19 pandemic on breast cancer incidence and tumor stage in the Netherlands and Norway
Eijkelboom A, de Munck L, Larsen M, Nygård J, Hofvind S, Siesling S. Netherlands Comprehensive Cancer Organisation (IKNL) | University of Twente; Netherlands Comprehensive Cancer Organisation (IKNL); Cancer Registry of Norway; Netherlands Comprehensive Cancer Organization (IKNL) | University of Twente, Department of Health Technology and Services Research.
P4-03-30 Patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer
Kaufman PA, Neuberger E, Hsu L-I, Schwartz N, Bartley K, Wang S, Liu Y, Blahna MT, Pittner BT, Wong G, Anders C. University of Vermont Cancer Center, Burlington, VT, USA; Seagen Inc.; Genesis Research; Duke University Medical Center / Duke Cancer Institute.
P4-03-31 Lifestyle factors are associated with breast cancer risk in women biopsied for benign breast diseases in China: 10-year results of a multi-center, hospital-based, case-control study
Zheng C, Ma D, Zhao L, Guo M, Cui S, Tian F, Fan Z, Geng C, Cao X, Yang Z, Wang X, Liang H, Wang S, Jiang H, Duan X, Wang H, Li G, Wang Q, Zhang J, Jin F, Tang J, Li L, Zhu S-G, Zuo W, Wang F, Yu L, Zhou F, Xiang Y, Guo M, Wang Y, Zhou W, Huang S, Li Z, Zhou Y, Hou L, Yang X, Zhang X, Liu L, Yu Z. Department of Breast Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University; Department of Ultrasound, Division of Life Science and Medicine, the First Affiliated Hospital of USTC, University of Science and Technology of China; Department of Breast Surgery, Affiliated Tumor Hospital of Zhengzhou University; Department of Breast Surgery, Shanxi Cancer Hospital; The First Hospital of Jilin University, Changchun, Jilin, China; Breast Center, the Fourth Hospital of Hebei Medical University; Tianjin Medical University Cancer Institute and Hospital; Department of Thyroid and Breast Surgery, the First Affiliated hospital of Binzhou Medical University; Department of Breast Surgery, Cancer Hospital, Chinese Academy of Medical Sciences; Department of General Surgery, Linyi People’s Hospital; Breast Disease Center, Peking University People's Hospital; Department of General Surgery, Beijing Chaoyang Hospital; Breast Disease Center, Peking University First Hospital; Breast Center, Qingdao University Affiliated Hospital; Department of Breast and Thyroid Surgery, Weifang Traditional Chinese Hospital; Department of Breast Surgery, the Second Affiliated Hospital of Qingdao Medical College, Qingdao Central Hospital; Department of General Surgery, the Second Affiliated Hospital of Harbin Medical University; Department of Breast Surgery, the First Affiliated Hospital of China Medical University; Department of General Surgery, Jiangsu Cancer Hospital; Department of Breast and Thyroid Surgery, Zibo Central Hospital; Department of Breast Surgery, Qindao University Medical College Affiliated Yantai Yuhuangding Hospital; Breast Cancer Center, Shandong Cancer Hospital; Department of Breast Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University.
P4-03-32 Association between androgen receptor expression and recurrence free survival among locally advanced triple negative breast. Real world data from a single Institution in Mexico City
Araiza Alvarado E, Arce Salinas CH. National Cancer Institute.
P4-03-33 A population-based analysis of prophylactic G-CSF biosimilar and originator administration over time among patients diagnosed with breast cancer
Pawloski PA, McDermott CL, Vazquez Benitez G, DeFor T, Mendelsohn AB, Marshall J, Moyneur E, Lockhart C. HealthPartners; Biologics and Biosimilars Collective Intelligence Consortium; Harvard Pilgrim Health Care Institute; Harvard Pilgrim Health Care; StatLog Inc.; Biologics and Biosimilars Collective Intelligence Consortium.
P4-03-34 Treatment patterns and associated outcomes among patients with HER2+ metastatic breast cancer in the United States
Lam C, Varghese D, Nordstrom BL, Murphy B, Collins J, Mehta S. AstraZeneca; AstraZeneca Pharmaceuticals LP, Gaithersburg, MD, USA; Evidera; Daiichi Sankyo, Inc.
P4-03-35 Withdrawn
P4-03-36 Determinants of severe COVID-19 infection in patients with breast cancer from a community oncology practice in Brazil
Cascelli F, Costa e Silva M, Dienstmann R, Ferrari BL, Ferreira CG, S.Mano M, Canedo J, Cunha D, Gimenes DL, Goncalves A. Grupo Oncoclínicas.
P4-03-37 The characteristics of male breast cancer by molecular subtypes: a population-based study
Wang M, Liu D, Zhu L. Department of Breast and Thyroid Surgery, Shanghai General Hospital, Shanghai JiaoTong University School of Medicine, Shanghai; Department of Breast and Thyroid Surgery, Shanghai General Hospital, Shanghai JiaoTong University School of Medicine.
P4-03-38 Rare breast cancer histologic subtypes: 30-year experience in a Mexican cancer center
Valdez-Sandoval P, Martinez-Cannon BA, Perez Alvarez SI, Leon-Rodriguez E. Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran.
P4-03-39 Breast density and body mass index association with breast cancer molecular subtypes in early  breast cancer Spanish population
Calvo I, González M, Neria F, Gallegos I, García-Sánchez L, Pérez S, Estévez LG. MD Anderson Cancer Center Madrid, Spain; Francisco de Vitoria University, Madrid, Spain; Segovia Hospital; San Pedro Hospital.
P4-03-40 Patient and treatment characteristics in HR+/HER2- metastatic breast cancer in a real-life setting
Karadurmus N, Sendur MAN, Cil T, Cakmak Oksuzoglu OB, Arslan C, Harputluoglu H, Sezgin Goksu S, Ozturk B, İnanç M, Cubukcu E, Demirci U, Erdem D, Cihan S, Tural D, Dumludag A, Aykan MB, Yılmaz F, Avsar E, Dinc Sonusen S, Ozturk OF, Aver B, Kaplan MA. University of Health Sciences Gulhane Training and Research Hospital, Medical Oncology Clinic, Ankara, Turkey; Ankara City Hospital, Medical Oncology Clinic, Ankara, Turkey; Adana City Training and Research Hospital, Medical Oncology Clinic, Adana, Turkey; University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey; Izmir Ekonomi University Medical Park Izmir Hospital, Medical Oncology Unit, Izmir, Turkey; Inonu University Turgut Ozal Medical Center Training and Research Hospital, Oncology Center, Malatya, Turkey; Akdeniz University Medical Faculty, Department of Medical Oncology, Antalya, Turkey; Antalya Training and Research Hospital, Medical Oncology Unit, Antalya, Turkey; Erciyes University Medical Faculty, Mehmet Kemal Dedeman Oncology Hospital, Department of Medical Oncology; Kayseri, Turkey; Uludag University Medical Faculty Hospital, Department of Medical Oncology, Bursa, Turkey; Ankara Memorial Hospital, Medical Oncology Center, Ankara, Turkey; VM Medical Park Samsun Hospital, Medical Oncology Unit, Samsun, Turkey; Istanbul Prof. Dr. Cemil Taşcıoğlu Şehir Hastanesi, Medical Oncology Unit, Istanbul, Turkey; Bakırköy Dr. Sadi Konuk Training and Research Hospital, Medical Oncology Unit, Istanbul, Turkey; University of Health Sciences Gulhane Training and Research Hospital, Medical Oncology Clinic; Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey; Antalya Training and Research Hospital, Medical Oncology Unit, Antalya, Turkey; Medical Oncology Department, Pfizer Pharmaceuticals, Istanbul, Turkey; Dicle University Medical Faculty, Department of Medical Oncology, Diyabakir, Turkey.
P4-03-41 Prospective observational study of breast cancer patients during the cycle of chemotherapy with taxanes: evaluation of the incidence and prevalence of peripheral neuropathy
Costa Luz RP, Alliz CS, Lopes de Almeida Rizzi SK, Haddad C, Bittencourt Machado C, Nazário A, Facina G. Federal University of Sao Paulo/ BR; Universidade Federal de Sao Paulo; Estácio University de Sá - Rio de Janeiro/BR.
P4-03-42 Evaluating the impact of race and body mass index on the diagnosis and prognosis of early onset breast cancer
Kordic A, Reyes A, Ashai N. MedStar Georgetown University Hospital; MedStar/ Georgetown University.
P4-03-43 Disease characteristics and outcomes of people with metastatic breast cancer in a single center cohort study: The Dallas Metastatic Breast Cancer Study
Cao M, Lim M, Moscowitz A, Ladner J, Hodgdon C, Maués J, Reddy SM, Chan I. University of Texas Southwestern Medical Center; Grasp Cancer.
P4-03-44 A case series of male breast cancer patients at Methodist Dallas Medical Center
Nong H, Moparty V, Manhas A. Methodist Dallas Medical Center; Texas Oncology - Methodist Dallas Medical Center.
   
  Psychosocial, Quality of Life, and Educational Aspects: Palliation and Pain Management
P4-04-01 Safety and efficacy of cryotherapy in the prevention and treatment of chemotherapy-induced peripheral neuropathy in breast cancer patients
Costa RB, Nogueira-Rodrigues A, Oliveira Bessa CP, Adalberto Menezes RC, Coelho de Miranda Jorge Oliveira F, Costa e Silva M, Rocha Paes F, Ferrari BL. Grupo Oncoclínicas.
P4-04-02 Evaluation of Dronabinol to decrease opioid use for cancer- induced bone pain
Segar J, Farr K, Junak M, Roe D, Ehsani S, Jiralerspong S, Mohab I, Vanderah T, Chalasani P. University of Arizona; University of Wisconsin; University of Arizona Cancer Center.
   
  Psychosocial, QOL, and Educational Aspects - QOL Issues: Psychosocial Aspects
P4-05-01 Cancer-related distress and unmet needs among triple negative breast cancer patients: Findings from the Cancer Experience Registry
Lawrence C, Fortune EE, Badt H, Doughtie K, Popalis ML, Miller MF. Cancer Support Community.
P4-05-02 Oncoplastic breast surgery and involvement of plastic surgery improve quality of life by Breast-Q score in breast conserving surgery
Stuntz ME, Rychkov TA, Garcia J. Community Hospital of the Monterey Peninsula; UC Berkeley; UC San Diego.
P4-05-03 Investigating financial toxicity among breast cancer patients diagnosed during the pandemic: The role of cancer care disruptions and social isolation
Acquati C, Chen T, Martinez Leal I, Connors S, Rogova A, Banegas M, Smith G, Reitzel LR, McNeill L. University of Houston; University of Houston-Downtown; University of California, San Diego; The University of Texas MD Anderson Cancer Center.
P4-05-04 Health-related quality of life and work impairment among individuals living with HER2+ breast cancer with brain metastases
Morris VG, Zaleta AK, Badt H. Cancer Support Community.
P4-05-05 The psycho-social factors impacting black women breast cancer survivors
Leach V. Tigerlily Foundation.
P4-05-06 Surgical outcomes for reconstruction after delayed contralateral prophylactic mastectomy
Soh CL, Muktar S,Malata CM, Benson JR. University of Cambridge; Cambridge University Hospitals.
P4-05-07 Making choices with scarce resources while battling breast cancer in Nigeria
Okwu GC, Nwosu-Zita TO, Haruna AE.
   
  Treatment - Therapeutic Strategies: Neoadjuvant Chemotherapy
P4-06-01 Platinum-based chemotherapy for early triple-negative breast cancer: A Cochrane systematic review and meta-analysis
Mason S. Willson M, Goodwin A, Beith J, Egger SJ, Dear RF. Garvan Institute of Medical Research, University of New South Wales; Systematic Reviews and Health Technology Assessments, NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia; Medical Oncology Department, Concord Repatriation General Hospital, Sydney, Australia. Concord Clinical School, University of Sydney, Concord Repatriation General Hospital, Concord, Australia. Cancer Genetics Department, Sydney Local Health District and South Western Sydney Local Health District, Sydney, Australia. Cochrane Breast Cancer Group; Chris O'Brien Lifehouse, Camperdown, NSW, Australia; Cancer Research Division, Cancer Council NSW, Sydney, Australia; Kinghorn Cancer Center, Darlinghurst, Australia. Sydney Medical School, The University of Sydney, Sydney, Australia.
P4-06-02 Complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis
Ploumen R, Claassens E, Kooreman L, Keymeulen K, van Kats M, Gommers S, Siesling S, van Nijnatten T, Smidt M. Maastricht University Medical Center+, Department of Surgery | GROW School for Oncology & Reproduction; Maastricht University Medical Center+, Department of Surgery; Maastricht University Medical Center+, Department of Pathology | GROW School for Oncology & Reproduction; Maastricht University Medical Center+, Department of Internal Medicine, Division of Medical Oncology; Maastricht University Medical Center+, Department of Radiology and Nuclear Medicine; Netherlands Comprehensive Cancer Organization (IKNL) | University of Twente, Department of Health Technology and Services Research; Maastricht University Medical Center+, Department of Radiology and Nuclear Medicine | GROW School for Oncology & Reproduction; Maastricht University Medical Center+, Department of Surgery | GROW School for Oncology & Reproduction.
P4-06-03 Pathological complete response (ypCR) in early and locally advanced breast cancer (LABC) patients treated with neoadjuvant chemotherapy in a middle-income country. Results from a real-world historical cohort
Mantilla W, Gonzalez M-F, Rojas S, Borras-Osorio M, Molano-Gonzalez N, Guerra J, Munevar I, Moran D. Fundación Cardioinfantil; Clinica Sanitas; Hospital Universitario Mayor MEDERI; Clinical Research Group, School of Medicine and Health Sciences, Universidad del Rosario; Los Cobos Medical Center; Fundación Cardioinfantil / Hospital Militar Central; Clinica Astorga.
P4-06-04 Clinical outcomes of loco-regional HER2-positive invasive lobular carcinoma of the breast
Gaire S, Budhathoki P, Joshi U, Shah A, Choong GM, Yadav S. Department of Internal Medicine, Mount Sinai Hospital Chicago; Department of Internal Medicine, Bronxcare Health System; Department of Internal Medicine, Rochester General Hospital; Mayo Clinic.
P4-06-05 Response to neoadjuvant chemotherapy among women with triple-negative breast cancer by HER2 expression status
Budhathoki P, Shah A, Gaire S, Joshi U, Yadav S. Department of Internal Medicine, Bronxcare Health System; Department of Internal Medicine, Mount Sinai Hospital Chicago; Department of Internal Medicine, Rochester General Hospital; Mayo Clinic.
P4-06-06 Neoadjuvant B27 protocol in triple-negative breast cancer: Evaluation response rate, pathological complete response rates ,toxicity ,and the prognosis of adolescent and young adult (AYA) age group compared to older population
Tamimi F, Sharaf B, Khater S, Al-Sawajneh S, Horani M, Elrabii KM, Zayed A, Abdel-Razeq H. King Hussien Cancer Center.
P4-06-07 Preliminary indications of safety and efficacy of neoadjuvant chemotherapy plus chemokine-modulating regimen (rintatolimod, IFN-α2b, celecoxib) in triple negative breast cancer
Gandhi S, Opyrchal M, Ford C, Slomba R, Attwood K, O'Connor T, Levine E, Kalinski P. Roswell Park Comprehensive Cancer Center; Indiana University School of Medicine.
P4-06-08 HER2-protein expression is a predictive marker for treatment response in patients with HER2-positive breast cancer who received neoadjuvant chemotherapy with dual HER2-blockade
Bae SJ, Jang JS, Kook Y, Baek SH, Kim JH, Ahn SG, Jeong J. Division of Breast Surgery, Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea; Gangnam Severance Hospital; Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine.
P4-06-09 A phase 1b study of neratinib with THP in metastatic and locally advanced breast cancer, and phase II study of THP followed by AC in HER2 + primary inflammatory breast cancer (IBC), and neratinib with taxol followed by AC in HR+ /HER2- IBC
Marx AN, Kai M, Fu M, Murphy HE, Willey JS, Sun H, Alexander A, Bassett Jr RL, Whitman GJ, Le-Petross HTC, Patel M, Arun BK, Abouharb S, Thomas PS, Barcenas CH, Ibrahim NK, Valero V, Ueno NT, Layman RM, Lim B, Woodward WA, Lucci A. The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center; Dan L. Duncan Comprehensive Cancer Center Baylor College of Medicine Houston, TX.
P4-06-10 Is Anthracycline chemotherapy essential in the treatment of women with breast cancer? – A real world comparison in the neoadjuvant setting
Giffoni D, Castelo M, Sutradhar R, Nguyen L, Faught N, Rodin D, Hahn E, Fatiregun o, Fong C, Trebinjac S, Eisen A, Paszat L, Jerzak K, Rakovitch E. Sunnybrook Health Sciences Centre; University of Toronto; Institute for Clinical Evaluative Sciences; University Health Network - Princess Margaret Cancer Centre; Princess Margaret Cancer Centre.
P4-06-11 Pathologic complete response in triple negative breast cancer of black vs white patients in the post-keynote 522 era
Sheen M, Chung V, Maini R, Duggan M, Levy J. Ochsner Clinic Foundation; Ochsner Health.
P4-06-12 Decision of neoadjuvant therapy in younger vs. older breast cancer patients: A real-world data analysis
Alanya E, Falcon-Lizaraso S, Aldecoa-Falcon S, Aldecoa-Bedoya F. Aliada Cancer Center; Universidad Peruana de Ciencias Aplicadas; Clinica Internacional.
P4-06-13 Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency – long-term survival of the GeparOLA study
Fasching PA, Schmatloch S, Hauke J, Rey J, Jackisch C, Klare P, Link T Hanusch C, Huober J, Stefek A, Seiler S, Schmitt WD, Uleer C, Doering G, Rhiem K, Schneeweiss A, Denkert C, Schmutzler RK, Hahnen E, Untch M, Nekljudova V, Blohmer J-U, Loibl S. Department of Obstetrics and Gynecology, University Hospital Erlangen, Erlangen, Germany; Elisabeth Krankenhaus Kassel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Uniklinik Köln, Germany; GBG Forschungs GmbH; Department of Obstetrics and Gynecology, Sana Klinikum Offenbach, Germany; MediOnko-Institut GbR Berlin; Department of Gynecology and Obstetrics, Technische Universität Dresden, Dresden, Germany; Rotkreuzklinikum München, Germany; Kantonsspital St.Gallen, Brustzentrum, Departement Interdisziplinäre medizinische Dienste, St. Gallen, Switzerland; Johanniter-Krankenhaus Genthin-Stendal, Germany; German Breast Group, Neu-Isenburg, Germany; Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Institute of Pathology, Berlin, Germany; Gemeinschaftspraxis Hildesheim, Germany; Hämato-Onkologie im Medicum Bremen, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Uniklinik Köln, Germany; National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany; Institut für Pathologie, Philipps Universität Marburg und Universitätsklinikum Marburg (UKGM), Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Uniklinik Köln, Germany; Helios Klinikum Berlin-Buch, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Charité - Universitätsmedizin Berlin; GBG Forschungs GmbH, Neu-Isenburg, Germany.
   
  Treatment - Treatment: Other
P4-07-01 Overall survival with locoregional surgery in de novo metastatic breast cancer
Chongxi R, Jianna S, Lingjun K. Cangzhou Clinical College of Integrated Traditional Chinese and Western Medicine of Hebei Medical University.
P4-07-02 Toxicity profile of single agent trastuzumab deruxtecan in solid tumors: A meta-analysis
Tamimi F, Mittal A, Molto Valiente C, Di Iorio M, Al-Showbaki L, Nadler M, Amir E. Princess Margaret Cancer Centre, Division of Medical Oncology, University of Toronto, Department of Medicine, Toronto, ON, Canada; Princess Margaret Cancer Centre, University of Toronto.
P4-07-03 The impact of HIV on non-adherence for tamoxifen among women with breast cancer in South Africa
Ayeni OA, Chiwambutsa S, CHen WC, Kapungu NN, Kanji C, Thelingwani R, Murugan N, Mathiba R, Phakathi B, Nietz S, Ramiah D, O'Neil DS, Jacobson JS, Ruff P, Cubasch H, Chirwa T, Joffe M, Masimirembwa C, Neugut AI. Wits Health Consortium/Soweto Comprehensive Cancer Centre, Johannesburg, South Africa; Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; University of the Witwatersrand; AiBST; African institute of Biomedical Science and Technology (AiBST); University of the Witwatersrand/Chris Hani Baragwanath Academic Hospital; Soweto Comprehensive Cancer Centre/ University of the Witwatersrand; University of the Witwatersrand; University of the Witwatersrand/Charlotte Maxeke Johannesburg Academic Hospital; University of Miami Miller School of Medicine; Columbia University; University of Witwatersrand, Faculty of Health Sciences; Wits University, Johannesburg, SA; University of the Witwatersrand, South Africa; Wits Health Consortium; African Institute of Biomedical Science and Technology/ University of Witwatersrand; Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University.
P4-07-04 STX-478, a mutant-selective PI3Kα H1047X inhibitor clinical candidate with a best-in-class profile: Pharmacology and therapeutic activity as monotherapy and in combination in breast cancer xenograft models
Buckbinder L, St. Jean Jr DJ, Ladd B, Tieu T, Jonsson P, Alltucker J, Manimala S, Wang W, Guzman-Perez A, Stuart DD, Dowdell G. Scorpion Therapeutics.
P4-07-05 Real world data of adjuvant endocrine therapy for breast cancer in very young women. A Chilean 20-year experience
Heredia A, Walbaum B, Acevedo F, Sánchez C. Pontificia Universidad Católica de Chile.
P4-07-06 Implementation of a bone modifying agent pathway at UChicago Medicine for metastatic breast cancer patients
Lin k, Baur J, Parsad S, Yang H. UChicago Medicine.
P4-07-07 Impact on overall survival according to sites of metastasis: Real-world data
Yagual Bohorquez L, Valencia-Espinoza E, Pulla-Cadmilema E, Velez Avila LP, Sanchez Salazar MdM, Tamayo Aguilar P, Martin-Delgado J, Ramos Martinez G, Garcia Matamoros K, Campoverde Merchan F, Engracia Vivanco R, Santacruz Maridueña M, Escala Cornejo R, Delgado Guerrero I, Torres Floril V, Garcia Gamboa D, Rodriguez-Melendez EA. Solca Guayaquil; Universidad Catolica Santiago de Guayaquil.
P4-07-08 Impact on overall survival according to breast cancer immunophenotypes: Real-world data in metastatic breast cancer in Ecuador
Valencia-Espinoza E, Pulla-Cadmilema E, Velez Avila LP, Yagual Bohorquez L, Sanchez Salazar MdM, Tamayo Aguilar P, Martin-Delgado J, Ramos Martinez G, Garcia Matamoros K, Escala Cornejo R, Campoverde Merchan F, Engracia Vivanco R, Santacruz Maridueña M, Delgado Guerrero I, Torres Floril V, Garcia Gamboa D, Rodriguez-Melendez EA. Solca Guayaquil; Universidad Catolica Santiago de Guayaquil.
P4-07-09 Identifying drivers of first-line HR+/HER2- metastatic breast cancer treatment choices
Brufsky AM, Maculaitis MC, Kopenhafer L, Olsen P, Cha AS, Arruda LS, Heck W, Kurosky SK. UPMC Hillman Cancer Center, University of Pittsburgh Medical Center; Cerner Enviza; Pfizer Inc.
P4-07-10 Effect of acupuncture and exercise therapy on muscular strength, lymphedema and quality of life in breast cancer survivors: randomized clinical trial
Santolia P, Facina G, Haddad C, Lopes de Almeida Rizzi SK, Nazário A, Elias S. UNIFESP; Universidade Federal de São Paulo.
P4-07-11 Disparities in the uptake of telemedicine and implications for clinical trial enrollment in breast cancer patients
Hardy Abeloos C, Xiao J, Oh C, Maisonet O, Gerber N. NYU Grossman School of Medicine; NYU Langone Health; Radiation Oncology, NYU Grossman School of Medicine.
P4-07-12 Development of triple-negative breast cancer (TNBC) syngeneic models and TROP2-directed antibody-drug conjugate (ADC) surrogate to model therapeutic combinations
Chou C-C, Kardos J, Yang B, Orf J, Dave R, Lai Y, Lee CV, Papalia GA, Boyd K, Diehl L, Scholler N. Gilead Sciences Inc., Foster City, CA, USA.
P4-07-13 Satisfaction of patients after implant-based subpectoral reconstruction with a titanized polypropylene mesh (TiLOOP® Bra) compared to prepectoral reconstruction with a titanzied polypropylene pocket (TiLOOP® Bra Pocket)
Paepke S, Andrulat A, Ankel C, Bauer L, Baumann K, Blohmer J-U, Faridi A, Fink V, Gerber-Schaefer C, Gschwantler-Kaulich D, Heil J, Kuemmel S, Kossmann-Meiré A, Ohlinger R, Thill M. Klinikum rechts der Isar, Department of Gynecology and Obstetrics, Technical University of Munich; Rotkreuzklinikum Munich; DRK Kliniken Berlin Westend; GRN Klinik Weinheim; Brustzentrum Luebeck; Charité - Universitätsmedizin Berlin; University hospital Bonn; University hospital Ulm; Vivantes Hospital am Urban, Berlin; University hospital Vienna; Department of Gynecology and Obstetrics, Breast Unit, Heidelberg University Hospital, Heidelberg, Germany; Evang. Kliniken Essen Mitte; St. Elisabeth-Krankenhaus Koeln-Hohenlind; University hospital Greifswald; Agaplesion Markus Krankenhaus Frankfurt.
P4-07-14 Long-term outcomes after 1 or 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer
Nakhlis F, Niman S, Ueno NT, Troll E, Ryan S, Yeh E, Warren L, Bellon J, Harrison B, Iwase T, Le-Petross HTC; Saleem S, Teshome M, whitman GJ, Woodward WA, Overmoyer B, Tolaney SM, Regan MM, Lynce F, Layman RM. DFCI/BWH; DFCI; The University of Texas MD Anderson Cancer Center, Houston, TX, USA; BWH; MD Anderson Cancer Institute; MD Anderson Cancer Institute; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; International Breast Cancer Study Group Statistical Center, Department of Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School.
P4-07-15 Withdrawn
P4-07-16 B-IMMUNE final analysis: a phase Ib/II study of durvalumab combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers
Devaux A, Beniuga G, Quaghebeur C, Henry S, Van Bockstal M, Galant C, Delrée P, Canon J-L, Honhon B, Korman D, Verschaeve V, Lonchay C, Lefevre S, D'Hondt L, Berlière M, Delmarcelle S, Mine J-M, Willems T, Müller G, Myant N, Bar I, Haussy S, Coulie PG, Duhoux FP, Carrasco J. Grand Hopital de Charleroi-GHdC site Notre Dame; Institut de Pathologie et Genetique - IPG; CHU UCL Namur - Site Ste Elisabeth; Cliniques universitaires Saint-Luc-institut Roi Albert II; Grand Hopital de Charleroi - GHdC site Notre Dame; CHU UCL Namur - site Mont Godinne; Cliniques universitaires Saint-Luc - Institut Roi Albert II; Institut de Duve UCLouvain.
P4-07-17 Follow-up in breast cancer care: guidelines and individual risks
Van Dongen L, Meijer J, Van Hoeve J, van den Bongard D, Hendriks M, Honkoop A, Strobbe L, Guerrero Paez C, Siesling S. University of Twente; Netherlands Comprehensive Cancer Organisation (IKNL); Amsterdam UMC; Bernhoven; Isala Clinics; Canisius Wilhelmina Hospital; Borstkankervereniging Nederland/Oncogen.
P4-07-18 FerOX, an anthracyclines nanoformulation to lead toward immuno-mediated cancer remission, preserving T-cell immune competence
Mazzucchelli S, Mainini F, Andreata F, Truffi M, Bonizzi A, Piccotti F, Sevieri M, Corsi F. University of Milan, Department of biomedical and Clinical Sciences; San Raffaele Scientific Institute; ICS Maugeri
P4-07-19 Eribulin enhances STING-dependent induction of type I interferons in immune and triple-negative breast cancer cells
Takahashi-Ruiz L, Fermaintt C, Wilkinson N, Mooberry S, Risinger A. UT Health San Antonio.
P4-07-20 Effect of prior treatments on post-CDK 4/6 inhibitor overall survival in hormone receptor positive breast cancer
Franks J, Caston NE, Elkhanany A, Gerke T, Azuero A, Rocque GB. University of Alabama at Birmingham; Prostate Cancer Clinical Trials Consortium.
P4-07-21 Neo-adjuvant chemotherapy in various breast cancer subtypes in the 21st century
Ananthula A, Thomas K, Chen L, Carey VK, Sullivan CM, Martin KM, Baas E, Plasko KC, Sun B, Lanza M, Nguyen C, Chapple A, Loch MM. LSUHSC, New Orleans.
P4-07-22 Clinical decision support systems for multidisciplinary team decision-making in patients with solid cancer: an implementation model based on a scoping review
Hendriks MP, Ebben KC, Van Til JA, Jager A, Siesling S. Northwest Clinics, Alkmaar; Dept. of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht; Dept. of Health Technology and Services Research, Technical Medical Center, University of Twente, Enschede; Erasmus MC Cancer Institute, Rotterdam, The Netherlands; Netherlands Comprehensive Cancer Organization (IKNL) | University of Twente, Department of Health Technology and Services Research.
P4-07-23 Results of a phase 2 trial of combination immunotherapy with concurrent Nelipepimut-S + GM-CSF and Trastuzumab in high-risk HER2+ breast cancer patients
Tiwari A, Clifton G, Calfa C, Alatrash G, Holmes J, Bedrosian I, Peoples G, Mittendorf EA. UT Health San Antonio; Brooke Army Medical Center; University of Miami Miller School of Medicine; MD Anderson Cancer Center; St. Joseph Hospital; Cancer Vaccine Development Program; Dana Farber Cancer Institute.
P4-07-24 Circulating tumor cells enumeration and Health Related Quality of Life of patients treated with first-line chemotherapy for HER2 negative metastatic breast cancer
Pierga J-Y, Billa O, Dabakuyo S, Lemonnier J, Berger F, Trédan O, Jacot W, Gonçalves A, Debled M, Levy C, Jouannaud C, Mouret-Reynier M-A, Ferrero J-M, Dalenc F, Toumi F-Z, Bonnetain F, Bidard F-C, Renault S. Institut Curie & Université Paris Cité; Centre George Francois Leclerc; R&D Unicancer; Institut Curie; Medical Oncology Department, Centre Léon Bérard, Lyon, France; Institut du Cancer de Montpellier, Université de Montpellier, INSERM U1194, Paris, France; Institut Paoli-Calmettes; Institut Bergonié; Centre François Baclesse; Institut Godinot; Centre Jean Perrin; Centre Antoine Laccassagne; Institut Claudius Régaud, Toulouse, France; R&D Unicancer; Centre de Recherche Lipides-Nutrition-Cancer.
P4-07-25 Performance of sentinel lymph node biopsy after neoadjuvant chemotherapy in clinically node positive breast cancer patients: Systematic review and meta-analysis
Zahwe M, Ghzaiel A, Ghezzawi M, El Iskandarani S, Diab M, Soueid L, El Jibbawi M, Najia A, El Asmar K, Sbaity E. American University of Beirut; Memorial Sloan Kettering Cancer Center; American University of Beirut Medical Center.
P4-07-26 Development of CDCP1-targeting antibody-drug conjugate for triple negative and metastatic breast cancer
Gough M, Khan T, Kwah K, He Y, Ratnayake G, Pyke C, Snell C, Hooper J, Kryza T. Mater Research Institute; PA Hospital; Mater hospital.
P4-07-27 Clipped lymph nodes for cN+ patients decrease false negative rate and lead to potential changes in surgical and oncological management after clinical complete response following neoadjuvant chemotherapy
Arienzo F, Campagna D, Scavinia P, Broglia L, Ascarelli A, Colavito H, Montanari M, Manna E, Mastropietro T, Zarba Meli E, La Pinta M, Musio D, Minelli M, Scavina P, Amato MMC, Costarelli L. Department of Radiological, Oncological and Pathological Sciences; Pathology; Oncology; Radiology; Surgery; Medical Oncologist.
P4-07-28 Prognostic impact of delaying multimodality treatment in HER2 positive breast cancer
Chang H, Gornbein J, Lim SY. David Geffen School of Medicine at UCLA; UCLA.
P4-07-29 Olaparib plus Trastuzumab in HER2[+] BRCA-Mutated Advanced Breast Cancer Patients: The OPHELIA Study
Alés-Martínez JE, Balmaña J, Sánchez-Rovira P, Salvador Bofill FJ, García-Sáenz JÁ, Pimentel I, Morales Murillo S, Fernández A, Lahuerta Martínez A, Ferrer N, Zamora P, Bermejo B, Díaz-Redondo T, Lopez-Ceballos MH, Galán M, Malfettone A, Calabuig L, Sampayo-Cordero M, Pérez-García JM, Cortés J, Llombart-Cussac A. Hospital Nuestra Sra. De Sonsoles, Ávila, Spain; Hospital Universitari Vall D'Hebron, Barcelona, Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital Universitario Virgen del Rocío, Seville, Spain; Hospital Clínico San Carlos; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Medical Oncology Department, Hospital Ramon y Cajal, Madrid, Spain; Alcalá de Henares University, Faculty of Medicine, Madrid, Spain; Onkologikoa, Guipuzkoa, Spain; Hospital Universitari Son Espases, Illes Balears, Spain; Hospital Universitario de La Paz, Madrid, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Unidad de Gestión ClínicaIntercentros de Oncología, Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Spain; Hospital San Pedro de Alcántara, Cáceres, Spain; Hospital Son Llàtzer, Barcelona, Spain; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain and Ridgewood, New Jersey, US; International Breast Cancer Center (IBCC), Quiron Group, Barcelona, Spain. Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain and Ridgewood, New Jersey, US; International Breast Cancer Center (IBCC), Barcelona, Spain; Hospital Arnau de Vilanova; FISABIO, Valencia, Spain. Catholic University, Valencia, Spain. Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain and Ridgewood, New Jersey, US.
P4-07-30 Features and survival outcomes of HER2-low patients from a prospective registry of unresectable locally advanced or metastatic breast cancer: GEICAM/2014-03 (RegistEM)
Álvarez I, Guerrero-Zotano A, Tibau A, Falo C, Hernández M, Miguel A, Andrés R, Rodríguez-Lescure Á; Corbellas M, López-Tarruella S, Martínez P, Rodríguez CA, Malón D, Marin M, Echarri AJ, Antón A, Cruz J, Moreno D, Chacón JI, Campo R, Blasco A, Bezares S, Rojo F, Antolin S. Hospital Universitario Donostia-BioDonostia. GEICAM Spanish Breast Cancer Group; Fundación Instituto Valenciano de Oncología (FIVO). GEICAM Spanish Breast Cancer Group; Hospital de la Santa Creu i Sant Pau. GEICAM Spanish Breast Cancer Group; ICO Hospitalet. GEICAM Spanish Breast Cancer Group; Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín. GEICAM Spanish Breast Cancer Group; ALTHAIA Xarxa asistencial de Manresa. GEICAM Spanish Breast Cancer Group; Hospital Clínico Universitario Lozano Blesa. GEICAM Spanish Breast Cancer Group; Hospital General Universitario de Elche. GEICAM Spanish Breast Cancer Group; Hospital Universitario Dr. Peset. GEICAM Spasnish Breast Cancer Group; Hospital Universitario Gregorio Marañón. CIBERONC-ISCIII. GEICAM Spanish Breast Cancer Group; Hospital Universitario Basurto; GEICAM Spanish Breast Cancer Group; Hospital Clínico Universitario de Salamanca-IBSAL, Salamanca, Spain; Hospital Universitario Fuenlabrada. GEICAM Spanish Breast Cancer Group; Consorci Sanitari de Terrassa. GEICAM Spanish Breast Cancer Group; Hospital Universitario Severo Ochoa. GEICAM Spanish Breast Cancer Group; Hospital Universitario Miguel Servet. GEICAM Spanish Breast Cancer Group; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Hospital Universitario Fuenlabrada. GEICAM Spanish Breast Cancer Group; Hospital Universitario de Toledo. GEICAM Spanish Breast Cancer Group; GEICAM Spanish Breast Cancer Group; The Autonomous University of Madrid; Oncology Department-Universitary Hospital A Coruña. GEICAM Spanish Breast Cancer Group.
P4-07-31 A whole food, plant-based (WFPB) dietary intervention to improve cardiometabolic and cancer-related outcomes in women with breast cancer
Campbell E, Campbell T, Culakova E, Wixom N, Guido J, Blanchard L, Fetten J, Janelsins M, Mustian K, Peppone L. University of Rochester School of Medicine and Dentistry; University of Rochester; Memorial Sloan Kettering Cancer Center.
P4-07-32 Prognostic factors among elderly patients with operable non-metastatic breast cancer treated with primary endocrine therapy
Andrade Rocha E, Monteiro Vasconcellos J, Vidaurre Mendes S, Galvão Freire PJ, Messias AP, Vecchi Leis L, Noschang Moreira O, Baptista Pereira M, Zanin Orsi B, Araujo Neto A, Petry V, Colombo Bonadio R, Testa L. Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil.
P4-07-33 Differences in treatment outcomes between patients with HER2-low versus HER2-zero, hormone receptor-positive advanced-stage breast cancer treated with CDK4/6 inhibitors
Sharaf B, Abu-Fares H, Tamimi F, Al-Sawajneh S, Salama O, Daoud R, Alhajahjeh AA, Al-Iababidi S, Abdel-Razeq H. King Hussien Cancer Center.
P4-07-34 CO2 laser, radiofrequency, and promestriene in treatment of genitourinary syndrome of menopause in breast cancer survivors. Clinical and histological aspects of a randomized control trial
Waitzberg AFL, Franco AFV, Bianchi-Ferraro AM, Marcela R, Cantarelli G, Dedonatto C, Patriarca M, Dardes R, Speck N, Jarmy-di Bella Z, Sartotti M, Almeida J. Universidade Federal de São Paulo.
P4-07-35 Changes in left ventricular global longitudinal strain in breast cancer patients receiving anti-HER2 and/or Adriamycin therapy and outcomes with early implementation of cardio-protective measures
Abunafeesa HE, Mckay C, Li P, Reddy M, Dabak V. Henry Ford Cancer Institute; Henry Ford Hospital; Department of Public Health Sciences, Henry Ford Hospital; Henry Ford Cancer Institute, Henry Ford Health System.
P4-07-36 Chest-wall and nodal irradiation in non-metastatic, node positive breast cancer patients with pathologic complete response after neoadjuvant chemotherapy and surgery, in a retrospective cohort of women aged 45 years and younger
Cerbon D, Sanchez-Covarrubias A, Conte B, Takita C, Freedman L, Meshman J, Samuels S, Shermoen C, Goel N, Carmona R, Wang L. University of Miami/Jackson Memorial Hospital; University of Miami; University Of Miami Radiation Oncology; University of Miami Department of Surgery.
P4-07-37 A UK study exploring the attitudes and experience of patients living with metastatic breast cancer with regard to clinical research: A patient advocate-academic collaborative study
Stephen L, Dunn JA, Balmer C, Gasson SJ, Elbeltagi NI, Copson ER, Palmieri C. Make 2nd Count; University of Warwick; Warwick Clinical Trials Unit, University of Warwick; University of Southampton; University of Liverpool.
P4-07-38 Real-world data of advanced breast cancer (ABC) patients with HER2-positivity before the second-line therapy: data from the observational study GEICAM/2014-03 (RegistEM)
López-Tarruella S, Guerrero-Sotano A, Cruz J, Antolin Novoa S, Martínez P, Hernández M, Rodríguez CA, Chacón JI, Tibau A, Falo C, Rodríguez-Lescure Á; Margelí M, Servitja S, Andrés R, Galán-Gramaje M, Adrover E, Miguel A, Villanueva R, Varela S, Campo R, Escudero MJ, Bezares S, Rojo F, Álvarez I. Hospital Universitario Gregorio Marañón. CIBERONC-ISCIII. GEICAM Spanish Breast Cancer Group; Fundación Instituto Valenciano de Oncología (FIVO). GEICAM Spanish Breast Cancer Group; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Complejo Hospitalario Universitario A Coruña (CHUAC). GEICAM Spanish Breast Cancer Group; Hospital Universitario Basurto. GEICAM Spanish Breast Cancer Group; Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín. GEICAM Spanish Breast Cancer Group; Hospital Universitario de Salamanca-IBSAL. GEICAM Spanish Breast Cancer Group; Hospital Universitario de Toledo. GEICAM Spanish Breast Cancer Group; Hospital de la Santa Creu i Sant Pau. GEICAM Spanish Breast Cancer Group; ICO Hospitalet. GEICAM Spanish Breast Cancer Group; Hospital General Universitario de Elche. GEICAM Spanish Breast Cancer Group; SOLTI Cancer Research Group. Medical Oncology Department, ICO Badalona, B-ARGO Group. GEICAM Spasnish Breast Cancer Group; Hospital del Mar, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa. GEICAM Spanish Breast Cancer Group; Hospital Son Llátzer. GEICAM Spanish Breast Cancer Group; Complejo Hospitalario Universitario de Albacete. GEICAM Spanish Breast Cancer Group; ALTHAIA Xarxa asistencial de Manresa. GEICAM Spanish Breast Cancer Group; Institut Català d'Oncologia. GEICAM Spanish Breast Cancer Group; Hospital Universitario Lucus Augusti. GEICAM Spanish Breast Cancer Group; GEICAM Spanish Breast Cancer Group; The Autonomous University of Madrid; Hospital Universitario Donostia-BioDonostia. GEICAM Spanish Breast Cancer Group.
P4-07-39 Neoadjuvant treatment in the COVID era
Alonso de Castro B, Gomez-Randulfe Rodriguez I, Silva Diaz S, Reboredo C, Antolin Novoa S, Perez Lopez E, Cordeiro P, Lesta R, Parajo Vazquez I, Calvo L. Complexo Hospitalario Universitario A Coruña; Oncology Department-Universitary Hospital A Coruña; Complejo Hospitalario Universitario A Coruña (CHUAC). GEICAM Spanish Breast Cancer Group; Complejo Hospitalario Universitario A Coruña; Oncology Department-Universitary Hospital A Coruña.
P4-07-40 Magnetic resonance imaging (MRI) and clinicopathological analysis of triple-negative breast cancer (TNBC) patients (pts) treated with primary anthracyclines(A)/taxanes(TX)-based chemotherapy
Sierra Boada M, Fernandez LA, Dalmau E, Llort G, Marin M, Andreu P, Lopez N, Climent C, Rodriguez M, Soriano S, Sequi MA. Hospital Universitari Parc Tauli Sabadell.
P4-07-41 Is axillary evaluation still necessary in DCIS?
Ramos M, Mattar A, Amorim A, Cavagna F, Passos M, Fernandes R, Shida J, Gebrim LH. Perola Byington Hospital.
P4-07-42 Intervention to distant metastatic lesions in patients with breast cancer
Abidi H, Ozbas S, Ozcinar B, Dogan L, Isik A, Diego E, McAuliffe PF, Johnson R, Steiman J, Sezgin E, Soran A. UPMC Magee Women's Hospital; Breast Health Working Group International; Istanbul University Istanbul Medical Faculty; University of Health Science - Ankara; Istanbul Medeniyet University; University of Pittsburgh; UPMC Department of Surgery, Breast Health Working Group International.
P4-07-43 Effect of acupuncture and exercise therapy in rehabilitation of physical disfunctions in breast cancer survivors: randomized clinical trial
Santolia P, Facina G, Haddad C, Nazário A, Lopes de Almeida Rizzi SK, Elias S. UNIFESP; Universidade Federal de São Paulo.
P4-07-44 Association between tissue mobilization with physical exercise and physical exercise alone in patients with axillary web syndrome who underwent breast cancer surgery
Figueira PV, Haddad C, Lopes de Almeida Rizzi SK, Estevao A, Elias S, Facina G, Nazário A. Universidade Federal de São Paulo.
P4-07-45 Treatment strategies for advanced triple negative breast cancer patients as per routine clinical practice: analysis from the observational study GEICAM/2014-03 (RegistEM)
Antolin Novoa S, Rodríguez CA, Cruz J, López-Tarruella S, Tibau A, Adrover E, Miguel A, Margelí M, Martínez P, Hernández M, Antón A, Rodríguez-Lescure Á; Falo C, Álvarez I, Malón D, Andrés R, Alonso-Romero JL, Gómez C, Illaramendi JJ, Campo R, Miralles, JJ, Bezares S, Rojo F, Guerrero-Zotano A. Complejo Hospitalario Universitario A Coruña (CHUAC). GEICAM Spanish Breast Cancer Group; Hospital Universitario de Salamanca-IBSAL. GEICAM Spanish Breast Cancer Group; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Hospital Universitario Gregorio Marañón. CIBERONC-ISCIII. GEICAM Spanish Breast Cancer Group; Hospital de la Santa Creu i Sant Pau. GEICAM Spanish Breast Cancer Group; Complejo Hospitalario Universitario de Albacete. GEICAM Spanish Breast Cancer Group; ALTHAIA Xarxa asistencial de Manresa. GEICAM Spanish Breast Cancer Group; SOLTI Cancer Research Group. Medical Oncology Department, ICO Badalona, B-ARGO Group. GEICAM Spasnish Breast Cancer Group; Hospital Universitario Basurto. GEICAM Spanish Breast Cancer Group; Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín. GEICAM Spanish Breast Cancer Group; Hospital Universitario Miguel Servet. GEICAM Spanish Breast Cancer Group; Hospital General Universitario de Elche. GEICAM Spanish Breast Cancer Group; ICO Hospitalet. GEICAM Spanish Breast Cancer Group; Hospital Universitario Donostia-BioDonostia. GEICAM Spanish Breast Cancer Group; Hospital Universitario Fuenlabrada. GEICAM Spanish Breast Cancer Group; Hospital Clínico Universitario Lozano Blesa. GEICAM Spanish Breast Cancer Group; Hospital Clínico Universitario Virgen de la Arrixaca. GEICAM Spanish Breast Cancer Group; Hospital Universitario Infanta Sofía. GEICAM Spanish Breast Cancer Group; Hospital Universitario de Navarra-Nafarroako Unibertsitate Ospitalea. GEICAM Spanish Breast Cancer Group; GEICAM Spanish Breast Cancer Group; The Autonomous University of Madrid; Fundación Instituto Valenciano de Oncología (FIVO). GEICAM Spanish Breast Cancer Group.
P4-07-46 The out-of-pocket cost of breast cancer care in Nigeria: A prospective analysis
Wuraola F, Blackman C, Owoade IA, Adeleye AO, Kingham P, Alatise O, Knapp G. Obafemi Awolowo University; Dalhousie University; African Research Group for Oncology; Memorial Sloan Kettering Cancer Center; Obafemi Awolowo University; Dalhousie University.
P4-07-47 Real-world practice patterns in the management of metastatic breast cancer in Washington State
Manohar P, Linden H, Shankaran V, Fedorenko C, Voutsinas J, Sun Q, Wu V. University of Washington; University of Washington, Fred Hutchison Cancer Center, Seattle, WA, USA; Fred Hutchinson Research Cancer Center.
P4-07-48 Preliminary results of the FIRST (FreezIng bReaST cancer in Brazil) trial: a before-after study
Sanvido VM, Bromberg SE, Junior AR, Tachibana BMT, Nazário A. Universidade Federal de São Paulo/ Hospital do Coração (Hcor); Hospital Israelita Albert Einstein de São Paulo; Universidade Federal de São Paulo.
P4-07-49 Neoadjuvant therapy in Asian breast cancer patients with early & locally advanced breast cancers – A contemporary experience from a large tertiary hospital in Singapore
Zhang Z, Ma J, Ting Tan JY, Ong WS, Kamis S, Yang G, Tee Tan BK, Tan VKM, Tan TJ. National Cancer Centre Singapore; National Cancer Centre, Department of Palliative Medicine.
P4-07-50 mRNA expression and delivery efficacy of lipid nanoparticles in the cells breast tumor microenvironment: in vitro and in vivo evaluation
Court KA, Tiwari A, Chau E, Cooke J, Godin B. Houston Methodist Research Institute.
P4-07-51 Impact of the Theralink CLIA protein/phosphoprotein assay on treatment selection in routine clinical practice: a prospective observational study in advanced breast cancer
Weinberg K, Pierobon M, Blais E, Davis J, O'Shaughnessy J, Petricoin EF. Theralink Technologies, Inc.; George Mason University; Perthera Inc; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX, USA; George Mason University.
P4-07-52 Caloric restriction for oncology research (CaReFOR): Assessing dietary adherence and outcomes in African American patients during breast cancer treatment
Harding S, Adekeye A, Mitchell EP, Simone N. TJU Hospital Radiation Oncology Department; Thomas Jefferson University.
P4-07-53 Adverse events (AEs) in phase III clinical trials of patients with human epidermal growth factor receptor-2 positive (HER2+) breast cancer (BC): a meta-analysis
Henderson M, Yalamanchili P, Wang E, Salas M. Daiichi Sankyo, Inc.; Daiichi Sankyo, Inc. & Rutgers Institute for Pharmaceutical Industry Fellowships.
P4-07-54 Health related quality of life of patients treated with bevacizumab and paclitaxel as first-line treatment for HER2 negative metastatic breast cancer: impact of clinical factors
BIlla O, Dabakuyo S, Chevrier M Bonnetain F, Desmoulins I, Jacot W, Trédan O, Debled M, Levy C, Gonçalves A, Ferrero J-M, Dalenc F, Jouannaud C, Mouret-Reynier M-A, Mousseau M, Grenier J, Jacquin J-P, Toumi F-Z, Berger F, Lemonnier J, Pierga J-Y. Centre George Francois Leclerc; Institut Curie; Centre de Recherche Lipides-Nutrition-Cancer; Institut du Cancer de Montpellier, Université de Montpellier, INSERM U1194, Paris, France; Medical Oncology Department, Centre Léon Bérard, Lyon, France; Institut Bergonié; Centre François Baclesse; Institut Paoli-Calmettes; Centre Antoine Laccassagne; Institut Claudius Régaud, Toulouse, France; Institut Godinot; Centre Jean Perrin; CHU Grenoble; Institut Sainte Catherine; Institut de cancérologie Lucien Neuwirth; R&D Unicancer; Institut Curie & Université Paris Cité.
P4-07-55 Neoadjuvant trastuzumab and pertuzumab in combination with anthracyclines in HER2-positive early breast cancer: real-world data on effect of body mass index in cardiac safety
Simão D, Sardinha M, Gil L, Montenegro A, Mendes J, Fernandes L, Winckler P, Luz R, Oliveira S. Centro Hospitalar Universitário de Lisboa Central.
P4-07-56 Mayo Clinic Enterprise patterns of growth-factor utilization for sacituzumab govitecan (SG)-induced neutropenia among patients with metastatic triple negative breast cancer
Clark K, Carroll JL, Moreno-Aspitia A, Ernst B, Raheem F, Heil A, Boyer B, Mara K, Goetz MP, Leon-Ferre RA, Giridhar KV, Taraba J. Mayo Clinic, Rochester, MN.
P4-07-57 Outcomes of triple-negative breast cancer in older versus younger women
Munir A, Khawaja S, Khan S, Sharaiha Y, Huws AM. Prince Philip Hospital; Hywel DDA University Health Board; Prince Philip Hospital.
P4-07-58 Adjuvant endocrine therapy adherence in breast cancer patients and the Brazilian National Health System
Herrera AC, Kasai CC, Gonçalves ET, Homa LA, de Oliveira CEE. Pontifícia Universidade Católica do Paraná / Grupo Oncoclinicas; Pontifícia Universidade Católica do Paraná - Campus Londrina; Pontifícia universidade católica do Paraná Londrina; Pontifícia Universidade Católica do Paraná.
P4-07-59 Management of isolated contralateral axillary lymph node metastasis in breast cancer: A single institution experience
Patel R, Berwick S, Jin C, Klein P. Icahn School of Medicine at Mount Sinai; Beth Israel Deaconeess Medical Center; Mount Sinai.
P4-07-60 Identification of optimal carboplatin containing regimen for triple negative breast cancer
Rempel GJ, Rim CS, Hussein A, Bocicariu A, Kulkarni S, Gupta R, Matthews J, Kay A, Porter L, Hamm C. University of Western Ontario; University of Windsor; Windsor Regional Hospital.
P4-07-61 Lymphedema, shoulder range of motion, pain, and presence of cords in patients undergoing breast cancer treatment with axillary web syndrome: Late follow-up
Figueira PV, Haddad C, Lopes de Almeida Rizzi SK, Estevao A, Elias S, Facina G, Nazário A. Universidade Federal de São Paulo.
P4-07-62 Real-world, single-center experience on the outcomes of neoadjuvant chemotherapy and Trastuzumab alone or in combination with Pertuzumab in human epidermal growth factor receptor 2 breast cancer patients
Vaid AK, Sharma D, Wadhwa J, Agarwal R, Kaur K, Goyal S, Gautam D, Arora J, Gupta S, Sen A, Goel RK, Mahajan S. Medanta – The Medicity Hospital.
P4-07-63 Local delivery of immunotherapeutics as an in situ vaccine in triple negative breast cancer
Mantooth s, Zaharoff D. NC State University.
P4-07-64 Impact of baseline ECOG, comorbidities, and surgery treatment election on overall survival
Rodriguez-Melendez EA, Pulla-Cadmilema E, Velez Avila LP, Sanchez Salazar MDM, Tamayo Aguilar P, Yagual Bohorquez L, Martin-Delgado J, Ramos Martinez G, Garcia Matamoros K, Santacruz Maridueña M, Engracia Vivanco R, Escala Cornejo R, Campoverde Merchan F, Delgado Guerrero I, Torres Floril V, Garcia Gamboa D, Pendola Gomez L, Gamarra Cabezas E, Garces Santos JC, Valencia-Espinoza E. Solca Guayaquil; Universidad Catolica Santiago de Guayaquil.
P4-07-65 Effect of sacituzumab govitecan vs chemotherapy in HR+/HER2- metastatic breast cancer: patient-reported outcomes from the TROPiCS-02 trial
Marmé F, Bardia A, Rugo HS, Schmid P, Tolaney SM, Oliveira M, Schneeweiss A, Shi L, Verret W, Gharaibeh M, Shah A, Cortés J. Med. Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany; Massachusetts General Hospital Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; Barts Cancer Institute, Queen Mary University of London; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Vall d'Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain; National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany; Department of Evidence Synthesis, Modeling & Communication, Evidera Inc, Waltham, MA, USA; Gilead Sciences Inc, Foster City, CA; Department of Global Value and Access, Gilead Sciences, Inc., Foster City, CA, USA; International Breast Cancer Center (IBCC), Barcelona, Spain, ), Pangaea Oncology, Quironsalud Group, Madrid and Barcelona, Spain & Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, Spain.
   
  Tumor Cell and Molecular Biology: Novel/Emerging Therapeutic Targets
P4-08-01 Targeting CDK7 enhances the antitumor efficacy of enzalutamide in androgen receptor-positive triple-negative breast cancer
Xie X, Manai M, Fuson JA, Pearson T, Rampa DR, Tripathy D, Lee J, Ueno NT. The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
P4-08-02 LOXO-783: A potent, highly mutant selective and brain-penetrant allosteric PI3Kα H1047R inhibitor in combination with standard of care (SOC) treatments in preclinical PI3Kα H1047R-mutant breast cancer models
Puca L, Dowless MS, Perez-Ferreiro CM, Ortiz-Ruiz MJ, Donoho GP, Capen A, Huber L, bogner SM, Fei D, Manro JR, Yu CP, Xu WG, Wang R, Chen S, Hicks II MA, Zolfaghari P, Faber A, Gilmour R, Ramstetter MD, Chang MT, Lallena MJ, Gong X, Hyman DM, Smyth LM, Brandhuber BJ, Taylor BS, Klippel A. Loxo@Lilly, Stamford, CT, USA; Eli Lilly and Company; Eli Lilly and Company, Spain; Eli Lilly China Research and Development Center.
P4-08-03 Operation of eIF4A1-PD-L1 axis in therapy-naïve and drug-resistant TNBC
Boring A, Dulal D, Raman D. University of Toledo College of Medicine and Life Sciences; University of Toledo.
P4-08-04 Withdrawn
P4-08-05 NOS inhibition reverses epithelial-to-mesenchymal transition and synergizes with alpelisib in metaplastic breast cancer
Reddy T, Puri A, Guzman L, Qian W, Zhou J, Rosato R, Zhao H, Thomas C, Li X, Mahboubi B, Oo A, Cho Y-J, Kim B, Thaiparambil J, Ayerbe C, Giese N, Moulder S, Piwnica-Worms H, Meric-Bernstam F, Chang J. Houston Methodist Research institute; Our Lady of Lourdes; Houston Methodist; Emory University; Lilly Oncology; The University of Texas MD Anderson Cancer Center, Houston, TX.
P4-08-06 Clock genes in breast cancer
Jayachandran P, Baca Y, Xiu J, Pan Y, Walker P, Battaglin F, Arai H, Khushman M, Le J, Spicer D, Mumenthaler S, Goldberg R, Weinberg B, Lou E, Hall M, Heeke AL, Korn WM, Kay SA, Lenz H-J, Roussos Torres ET. University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Caris Life Sciences; University of Alabama; ; Lawrence J. Ellison Institute for Transformative Medicine, Norris Comprehensive Cancer Center; West Virginia University; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center; University of Minnesota; Fox Chase Cancer Center; Levine Cancer Institute, Atrium Health; University of Southern California Michelson Center for Convergent Bioscience.
P4-08-07 Inhibition of the NUDT5 phosphatase suppresses the growth of triple-negative breast cancers
Qian J, Brown P. The University of Texas MD Anderson Cancer Center; MD Anderson Cancer Center, Department of Clinical Cancer Prevention.
P4-08-08

Moved to HER2 Session 


P4-08-09 Deoxycytidine kinase (dCK) inhibition is synthetic lethal with BRCA2-deficiency
Guantay ML, Garro CA, Siri S, Pansa M, Ghidelli-Disse S, Paviolo N, Racca A, Nicotra V, Radu C, Bocco JL, Felice R, Gloger I, Muelbaier M, Drewes G, Madauss K, García M, Gottifredi V, Soria G. CIBICI-CONICET; OncoPrecision; Fundación Instituto Leloir-CONICET; GlaxoSmithKline, Global Health R&D (US); Cellzome GmbH- a GSK Company; IMBIV-CONICET; University of California, Los Angeles; GlaxoSmithKline, Southern Cone LatAm; GlaxoSmithKline, Global Health R&D (UK); Cellzome GmbH- a GSK Company; OncoPrecision / CIBICI-CONICET.
P4-08-10 Azeliragon (TTP488), an orally- available small molecule RAGE inhibitor, reduces metastasis in preclinical mouse models of breast cancer
Magna M, Hwang GH, McIntosh A, Drews-Elger K, Takabatake M, Mera B, Kwak T, Miller P, Lippman M, Hudson BI. Georgetown University; University of Miami.
P4-08-11 AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution
Schade A, Perurena N, Watanabe M, Rodriguez CL, Loi P, Pilla N, Davis RA, Mattioli K, Xiang D, Zoeller JJ, Li Zhe, Garrido-Castro AC, Tolaney SM, Cichowski K. Brigham and Women's Hospital; Harvard Medical School; Harvard University; Dana-Farber/Brigham and Women’s Cancer Center; Harvard Medical School; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Brigham and Women's Hospital; Harvard Medical School.
P4-08-12 Clinical and genomic landscape of breast cancers carrying CCNE1 amplification
Marra A, Selenica P, Zhu Y, Razavi P, Safonov A, Ferraro E, Chandarlapaty S, Reis-Filho J. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
P4-08-13 Withdrawn
P4-08-14 Overcoming drug transport barriers in breast cancer liver metastasis by using macrophages as carriers: valuation in 2D and 3D models
Tiwari A, Chau E, Court KA, Carr J, Goodin D, Frieboes H, Godin B. Houston Methodist Research Institute; University of Louisville.
P4-08-15 Identification of target kinases whose inhibition enhances antitumor efficacy of sacituzumab-govitecan in metastatic HER2-negative breast cancer
Oh N, Fuson JA, Liu H, Tripathy D, Ueno NT, Lee J. The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
P4-08-16 Selective Androgen Receptor Modulators in combination with CDK4/6 inhibitors demonstrate anti-cancer activity in preclinical treatment resistant ER+AR+ breast cancer models
Freelander A, Iaven-Law G, Eshraghi L, Geetha N, Somerville P, Pickering M, Alexandrou S, Caldon CE, Tilley WD, Hickey TE, Lim E. Garvan Institute of Medical Research; Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide; Garvan Institute of Medical Research, St Vincent's Clinical School, University of New South Wales, Darlinghurst, Australia.
P4-08-17 Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer
Larsson P, Pettersson D, Olsson M, Forssell-Aronsson E, Kovács A, Karlsson P, Helou K, Parris TZ. Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden; Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
P4-08-18 Engineered toxin bodies specific for TROP2 positive cancers
Cornelison GL, Pedraza I, Garrison K, Kapeel EM, Pletka C, Khan A, Momb J, Martin R, Bartos A, Dekker JD, Zhao J, Majercak J, Robinson GL.
P4-08-19 Biomarker analysis: Multi-omics elucidation of Cohort 1 from a phase II study of a triple combination of Atezolizumab + cobimetinib + eribulin in patients with metastatic inflammatory breast cancer
Lim B, Alexander A, Willey JS, Sun H, Liu S, Patel AB, Parra ER, Haymaker C, Solis Soto L, Serrano A, Sun B, Pinto Lima CF, Tamegnon A, Pandurengan RK, Douse D, Lan J, Raja L, Chu R, Knafl M, Woodman SE, Zhu H, Shulze K, Fedenko K, Darbonne W, Ueno NT, Valero V. Dan L. Duncan Comprehensive Cancer Center Baylor College of Medicine Houston, TX; The University of Texas MD Anderson Cancer Center, Houston, TX, USA; US Medical Affairs, Roche/Genentech; Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center.
P4-08-20 Inhibition of TACC3 blocks the growth of highly aggressive breast cancers with centrosome amplification
Saatci O, Akbulut O, Cetin M, Sikirzhytski V, Sahin O. Medical University of South Carolina; University of South Carolina.
P4-08-21 Development of novel inhibitors of the serum/glucocorticoid induced kinase (SGK) family to address limitations of AKT/PI3K/mTOR inhibitors in breast cancer
Labit D, Pradhananga S, Khalifa M, Blackburn E, Sajid N, Vidal M, Odink D, Campeau E. Thryv Therapeutics.
P4-08-22 Expression of dual specific phosphatase-7 (DUSP7/PYST2) and it’s connection with salt inducible kinases (SIKs) and downstream MKKs in breast cancer
Ji W, Lin L, Davies E, Jiang WG, Ye L. Cardiff University; Breast Disease Centre of Peking University First Hospital; Wales Breast Centre, University Llandough Hospital, Cardiff CF64 2XX, UK.
P4-08-23 ZHX2 promotes HIF1α oncogenic signaling in triple-negative breast cancer
Liao C, Fang W, Shi R, Simon J, Ptacek T, Zurlo G, Ye Y, Han L, Fan C, Bao L, Ortiz CL, Lin H-R, Manocha U, Luo W, Peng Y, Kim WY, Yang L-W, Zhang Q. UT Southwestern Medical Center; The First Affiliated Hospital of Nanjing Medical University; University of North Carolina School of Medicine; Shanghai Jiao Tong University; The University of Texas Health Science Center; National Tsing Hua University; University of North Carolina at Chapel Hill; University of North Carolina School of Medicine.
P4-08-24 Palmitoylation of Flotillin-1 contributes to  breast cancer metastasis
McClellan B. University of Texas at Austin.
   
  Tumor Cell and Molecular Biology: Tumor Heterogeneity/Molecular Subclassification
P4-09-01 Moved to HER2 Session
P4-09-02 A molecular classification system for basal-like breast cancer based on the tumor microenvironment is prognostic for survival
Khorkova S, Shamsutdinova D, Kushnarev V, Popyvanov L, Dymov D, Zotova A, Valiev I, Antysheva Z, Love A, Brown JH, Bagaev A, Kotlov N, Fowler N. BostonGene, Corp.
P4-09-03 Survival differences between HER2-zero and HER2-low-expressing breast cancer—A meta-analysis of early breast cancer patient data from 12 studies including 39831 patients
Zhang X, Yang C, Wang K. Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China.
P4-09-04 Correlation between histology and molecular subtypes in triple negative breast cancer
Domingos TA, Pimenta Peixoto RB, Patel A, Taneja K, Chen WY, Mittendorf EA, Zimbalist A, Cespedes Feliciano EM, Dillon DA. Department of Pathology, Brigham and Women's Hospital; Dana-Farber Cancer Institute; Kaiser Permanente Northern California Division of Research; Brigham and Women's Hospital, Breast Oncology Program, Susan F. Smith Center for Women's Cancers, Dana-Farber Brigham Cancer Center; Harvard Medical School.
P4-09-05 Characterization and validation of biologically-driven HER2-positive breast cancer subgroups in the ALTTO and NeoALTTO clinical trials
Rediti M, Venet D, Joaquin Garcia A, Agbor-Tarh D, Maetens M, Vincent D, Majjaj S, El-Abed S, Ueno T, Di Cosimo S, Piccart M, Pusztai L, Loi S, Salgado R, Viale G, Rothé F, Sotiriou C. Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Frontier Science Scotland, United Kingdom; Laboratory for Translational Breast Cancer Research, KU Leuven, Leuven, Belgium; Breast International Group BIG, Brussels, Belgium; Breast Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; Biomarker Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Institut Jules Bordet – Université Libre de Bruxelles, Brussels, Belgium; Yale University Cancer Center, New Haven, CT, USA; Peter MacCallum Cancer Centre, Melbourne, Australia; GZA-ZNA-Hospitals, Antwerp, Belgium; Peter Mac Callum Cancer Centre, Melbourne, Australia; European Institute of Oncology IRCCS, and University of Milan, Milan, Italy.
P4-09-06 Moved to HER2 Session
P4-09-07 Characterization of immune contexture in HR+/HER2- and triple negative breast cancer in a real-world cohort
Chhibber A, Dillon LM, Wojcik JB, Dostal V, Lee G, Seifuddin F, Ely S, Stern MD, Benson-Garnett C, Roberts M, Wu J. Bristol Myers Squibb; Parexel International.
P4-09-08 AI-based quantitation of cancer cell and fibroblast nuclear morphology reflects transcriptomic heterogeneity and predicts survival in breast cancer
Abel J, Kirkup C, Kos F, Gerardin Y, Srinivasan S, Brosnan-Cashman J, Leidal K, Vasudevan S, Rajan D, Jain S, Prakash A, Padigela H, Conway J, Patel N, Trotter B, Yu L, Taylor-Weiner A, Krause EL, Bronnimann M, Chambre L, Glass B, Parmar C, Hennek S, Khosla A, Resnick M, Beck AH, Montalto M, Najdawi F, Drage MG, Wapinski I. PathAI.
P4-09-09 Withdrawn
P4-09-10 Spatial protein and RNA expression in tumor, immune and stromal cells in BRCA1/2 mutated metastatic breast cancer
Collier KA, Miller K, Li Z, Westfall J, Tallman D, Vater M, Tinoco G, Mardis E, Stover DG. The Ohio State University; Nationwide Children's Hospital Institute for Genomic Medicine; Ohio State University Comprehensive Cancer Center.
P4-09-11 Development of personalized medicine for breast cancer based on elucidation of resistance mechanisms to CDK4/6 inhibitors
Kobayashi Y, Motoi Y, Fujimoto M, Shigematsu H. Department of Breast Surgery and Oncology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan; Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
P4-09-12 Baseline and end-of-treatment biomarkers in patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer from BYLieve Study Cohorts A and B
Juric D, Turner NC, Loi S, Andre F, Chia SK, Jhaveri K, Neven P, Dent R, Ciruelos E, Joshi M, Roux E, Patino H, Akdere M, Rugo HS. Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, MA, USA; Institute of Cancer Research, Royal Marsden Hospital, London, UK; Peter MacCallum Cancer Centre, Melbourne, Australia; Institut Gustave Roussy, Villejuif, France; British Columbia Cancer Agency, Vancouver, BC, Canada; Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Multidisciplinary Breast Center, University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium; National Cancer Center Singapore; SOLTI Breast Cancer Research Group, Barcelona, Spain / Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain; Novartis Institutes for BioMedical Research, Cambridge, MA, USA; Novartis; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.